A type of pentacyclic triterpenoid carbonyl glycoside compound and its preparation method and use
By developing pentacyclic triterpene carbonin derivative compounds, the problems of existing drugs being unstable in the body and poor antiviral effects are solved, effective control of diabetes and viruses is achieved, and good metabolic stability and anti-viral stability are achieved. Viral activity.
Patent Information
- Application Number
- CN202110758853.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-07-07
- Filing Date
- 2021-07-05
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2041-07-05
AI Technical Summary
Existing diabetes and antiviral drugs are metabolized in the body without stable metabolism, making it difficult to effectively control blood sugar levels and inhibit viruses, and their resistance to viruses develops rapidly, and there is a lack of effective targeted small-molecule compounds.
Develop a pentacyclic triterpene glycoside derivative compound shown in the general formula I, which prevents the virus from entering the host cell by binding to hemagglutinin and coronavirus N protein, and has good metabolic stability and antiviral activity. for the treatment of diabetes and antivirals.
It achieves good metabolic stability and antiviral effects in the body, can effectively reduce blood sugar levels and inhibit viral replication, and has high target specificity, reducing the occurrence of drug resistance.
Smart Images

Figure CN113896757B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medicinal chemistry and medicine, and in particular to a class of pentacyclic triterpene carbon glycoside compounds, a preparation method thereof, and the effects of treating metabolic diseases and antiviral effects thereof, in particular to the use of the compounds for preparing medicines for treating diseases such as diabetes, influenza, and pneumonia caused by coronavirus. Background Art
[0002] Diabetes Mellitus (DM) is a chronic, systemic, metabolic disease caused by the long-term combined effects of genetic and environmental factors. It is characterized by increased plasma glucose levels and is mainly caused by the disorder of sugar, fat, and protein metabolism caused by insufficient insulin secretion or dysfunction (insulin resistance) in the body, which affects normal physiological activities. The complications of diabetes can be divided into acute complications and chronic complications. Among them, acute complications include diabetic ketoacidosis, diabetic hyperosmolar coma, various acute infections and lactic acidosis. In addition, hypoglycemia that occurs during the treatment of diabetes is also one of the most common acute complications; chronic complications include diabetic eye disease, diabetic nephropathy, diabetic mental morbidity, diabetic cardiovascular and cerebrovascular lesions, diabetic foot and skin lesions, etc. The main clinical manifestations of diabetes are polydipsia, polyuria, polyphagia and weight loss.
[0003] Diabetes is divided into insulin-dependent diabetes mellitus (IDDM, i.e. type I diabetes) and non-insulin-dependent diabetes, which are the most common and account for more than 90% of diabetic patients. The exact cause and pathogenesis of type I diabetes are not very clear. Its cause is caused by the joint participation of genetic and environmental factors, mainly due to the damage of pancreatic b cells in the body, which leads to the inability to produce insulin in the body. Patients need to inject insulin every day to control the insulin level in their blood. Type II diabetes is a type of metabolic syndrome caused by the inability to control blood sugar levels in the body. The main characteristics are high blood sugar, insulin resistance and lack of insulin secretion. The cause of type II diabetes is mainly due to insulin resistance, which makes the body unable to effectively use insulin, or the reduction of insulin secretion cannot meet the body's needs. Since this type of diabetic patients can secrete insulin, generally no insulin treatment is required, and blood sugar can be controlled by only dietary adjustments or oral hypoglycemic drugs.
[0004] Pentacyclic triterpenoids are secondary plant metabolites found in a variety of plant organs, with some species containing up to 30% of their dry weight. Although the molecular mechanism is still unclear, triterpenoids are generally considered to be an important part of the plant's defense system against pathogens and herbivores. Some reports have pointed out that some glycoside pentacyclic triterpenoids have in vitro anti-influenza virus activity comparable to or higher than oseltamivir. Mechanistic studies have shown that these compounds bind tightly to the hemagglutinin (HA) protein, thereby disrupting the interaction between hemagglutinin and sialic acid receptors and preventing the virus from entering the host cell, a process that is not prone to drug resistance. At the same time, studies have shown that pentacyclic triterpenoids can bind to the N protein of the coronavirus, preventing the assembly of the virus and achieving an anti-coronavirus effect. At the same time, the N protein of the coronavirus is highly conserved and plays an important role in immunity, so compounds targeting the N protein are very promising small molecule antiviral compounds.
[0005] For carbohydrate drugs, oxygen glycosides and nitrogen glycosides are easily oxidized and metabolized in the body, while carbon glycosides show good metabolic stability both in vivo and in vitro, which makes carbon glycosides widely concerned by scientists. Therefore, pentacyclic triterpene carbon glycosides have a very bright prospect in the research and development of hypoglycemic drugs and antiviral drugs.
[0006] In summary, there is an urgent need in the art to develop novel pentacyclic triterpene glycoside compounds. Summary of the invention
[0007] The object of the present invention is to provide a pentacyclic triterpene carbon glycoside derivative compound represented by general formula I or a pharmaceutically acceptable salt, racemate, R-isomer or S-isomer or a mixture thereof.
[0008] In the first aspect of the present invention, there is provided a pentacyclic triterpene carbon glycoside derivative compound having a structure as shown in the following general formula I, or its racemate, R-isomer, S-isomer, pharmaceutically acceptable salt or mixture thereof:
[0009]
[0010] in,
[0011] Ring A is selected from the following group: 6-membered saturated carbocyclic ring or unsaturated carbocyclic ring;
[0012] R1, R2 and R3 are each independently selected from the group consisting of hydrogen and methyl; R4 is selected from the group consisting of hydrogen and isopropenyl;
[0013] R5 is selected from the following group: hydrogen, deuterium, tritium, halogen, cyano, amino, nitro, hydroxyl, thiol, aldehyde, carboxyl, sulfonyl, phosphate, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C6-C 10 aryl, substituted or unsubstituted 5-7 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted C1-C6 alkyl-phenyl, substituted or unsubstituted C3-C 12 Cycloalkyl, substituted or unsubstituted C2-C 10 Acyl, substituted or unsubstituted C2-C 10 Ester group, substituted or unsubstituted C6-C 10 Aryloxy, substituted or unsubstituted C1-C6 amide, or Y-R7; wherein:
[0014] Y is selected from the group consisting of: -(CH2) m CHR9-, carbonyl, -CONH-, -COO-;
[0015] Where m is 0 or 1;
[0016] R7 is selected from the following groups: hydrogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted 5-7 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted C2-C 10 ester group, substituted or unsubstituted C5-C9 furanosyl group, substituted or unsubstituted C5-C9 pyranosyl group;
[0017] Z is selected from the group consisting of carbonyl, -CH(R9)2, C=N-R8, C=N-NH-R8, or -X-R6;
[0018] R8 is selected from the following group: hydrogen, deuterium, tritium, halogen, cyano, amino, nitro, hydroxyl, thiol, aldehyde, carboxyl, sulfonyl, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-7 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted C1-C6 alkyl-phenyl, substituted or unsubstituted C3-C12 cycloalkyl, substituted or unsubstituted C2-C10 acyl, substituted or unsubstituted C2-C10 ester, substituted or unsubstituted C6-C10 aryloxy, substituted or unsubstituted C1-C6 amide;
[0019] R9 is selected from the group consisting of hydrogen, deuterium, tritium, halogen, cyano, amino, nitro, hydroxyl, and mercapto;
[0020] R6 is selected from the following group: hydrogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted 5-7 membered heterocycle containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted C5-C9 furanose group, substituted or unsubstituted C5-C9 pyranose group; the substitution refers to one or more hydrogen or hydroxyl groups on the sugar ring being replaced by a substituent selected from the following group: hydrogen, deuterium, tritium, halogen, cyano, amino, nitro, thiol, aldehyde, carboxyl, benzyl, substituted or unsubstituted C1-C 12 Alkoxycarbonyl, substituted or unsubstituted C2-C 12 Alkylaminocarbonyl, substituted or unsubstituted C2-C 10 Acyl, sulfonyl, phosphoryl, C5-C9 furanosyl, C5-C9 pyranosyl;
[0021] X is selected from the group consisting of -CHR9-, carbonyl, S, -NHC(O)-R8, -NHS(O)2-R8, -NHC(O)NH-R8, -NHC(S)NH-R8, -COO-, -OS(O)2-R8;
[0022] n is 1 or 2;
[0023] Unless otherwise specified, in the above formulae, the substitution refers to the substitution of a hydrogen atom on the corresponding group or a hydroxyl group on the sugar ring by one or more substituents selected from the group consisting of deuterium, tritium, halogen, hydroxyl, carboxyl, thiol, benzyl, C1-C 12 Alkoxycarbonyl, C1-C6 aldehyde, amino, C1-C6 amide, nitro, cyano, unsubstituted or halogenated C1-C6 alkyl, C2-C 10 Alkenyl, C1-C6 alkoxy, C1-C6 alkyl-amino, C6-C 10 aryl, five-membered or six-membered heteroaryl, five-membered or six-membered non-aromatic heterocyclic group, -O-(C6-C 10 aryl), -O-(five-membered or six-membered heteroaryl), C1-C 12 Alkylaminocarbonyl, substituted or unsubstituted C2-C 10 Acyl, sulfonyl (-SO2-OH), phosphoryl (-PO3-OH), C5-C9 furanosyl, C5-C9 pyranosyl.
[0024] In another preferred embodiment, the compound of formula I has a structure shown in the following general formula II:
[0025]
[0026] in:
[0027] R5 is selected from the following group: hydrogen, deuterium, tritium, halogen, cyano, amino, nitro, hydroxyl, thiol, aldehyde, carboxyl, sulfonyl, phosphate, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-7 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted C1-C6 alkyl-phenyl, substituted or unsubstituted C3-C12 cycloalkyl, substituted or unsubstituted C2-C10 acyl, substituted or unsubstituted C2-C10 ester, substituted or unsubstituted C6-C10 aryloxy, substituted or unsubstituted C1-C6 amide;
[0028] X is selected from the group consisting of -CHR9-, carbonyl;
[0029] R6 is selected from the group consisting of substituted or unsubstituted C5-C9 furanose, substituted or unsubstituted C5-C9 pyranose; the substitution refers to one or more hydrogen or hydroxyl groups on the sugar ring being replaced by a substituent selected from the group consisting of hydrogen, deuterium, tritium, halogen, cyano, amino, nitro, sulfhydryl, aldehyde, carboxyl, benzyl, substituted or unsubstituted C1-C12 alkoxycarbonyl, substituted or unsubstituted C2-C12 alkylaminocarbonyl, substituted or unsubstituted C2-C10 acyl, sulfonyl, phosphoryl, C5-C9 furanose, C5-C9 pyranose;
[0030] R9 is selected from the group consisting of hydrogen, deuterium, tritium, halogen, cyano, amino, nitro, hydroxyl, and mercapto;
[0031] Ring A is selected from the following group: 6-membered saturated carbocyclic ring or unsaturated carbocyclic ring;
[0032] n is 1 or 2.
[0033] In another preferred embodiment, the compound of formula I has a structure shown in the following general formula III:
[0034]
[0035] in:
[0036] R1, R2 and R3 are each independently selected from the group consisting of hydrogen, methyl;
[0037] R4 is selected from the group consisting of hydrogen, isopropenyl;
[0038] R7 is selected from the group consisting of hydrogen, substituted or unsubstituted C5-C9 furanose, substituted or unsubstituted C5-C9 pyranose; the substitution means that one or more hydrogen or hydroxyl groups on the sugar ring are replaced by a substituent selected from the group consisting of hydrogen, deuterium, tritium, halogen, cyano, amino, nitro, sulfhydryl, aldehyde, carboxyl, benzyl, substituted or unsubstituted C1-C12 alkoxycarbonyl, substituted or unsubstituted C1-C12 alkylaminocarbonyl, substituted or unsubstituted C2-C10 acyl, sulfonyl, phosphoryl, C5-C9 furanose, C5-C9 pyranose;
[0039] Y is selected from the group consisting of: -(CH2) m CHR9-, carbonyl;
[0040] m is 0 or 1;
[0041] R9 is selected from the group consisting of hydrogen, deuterium, tritium, halogen, cyano, amino, nitro, hydroxyl, and mercapto;
[0042] Z is selected from the group consisting of carbonyl, -CH(R9)2, =N-R8, or -X-R6;
[0043] R9 is selected from the group consisting of hydrogen, halogen, cyano, amino, nitro, hydroxyl, and mercapto;
[0044] X is selected from the group consisting of -CHR9-, carbonyl, S, -NHC(O)-R8, -NHS(O)2-R8, -NHC(O)NH-R8, -NHC(S)NH-R8, -COO-, -OS(O)2-R8;
[0045] R6 is selected from the following group: hydrogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted 5-7 membered heterocycle containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted C5-C9 furanose group, substituted or unsubstituted C5-C9 pyranose group; the substitution refers to one or more hydrogen or hydroxyl groups on the sugar ring being replaced by a substituent selected from the following group: hydrogen, deuterium, tritium, halogen, cyano, amino, nitro, thiol, aldehyde, carboxyl, benzyl, substituted or unsubstituted C1-C 12 Alkoxycarbonyl, substituted or unsubstituted C2-C 12 Alkylaminocarbonyl, substituted or unsubstituted C2-C 10 Acyl, sulfonyl, phosphoryl, C5-C9 furanosyl, C5-C9 pyranosyl;
[0046] Ring A is selected from the following group: 6-membered saturated carbocyclic ring or unsaturated carbocyclic ring;
[0047] n is 1 or 2.
[0048] In another preferred embodiment, the compound of formula I has a structure shown in the following general formula IV, V or VI:
[0049]
[0050] In another preferred embodiment, R5 is selected from the following group: hydrogen, halogen, hydroxyl, carboxyl, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C10 acyl, substituted or unsubstituted C2-C10 ester, substituted or unsubstituted C1-C6 amide.
[0051] In another preferred embodiment, R9 is selected from the group consisting of hydrogen, hydroxyl, aldehyde, thiol, or -X-R6;
[0052] X is selected from the group consisting of -CHR9-, carbonyl, S, -NHC(O)-R8, -NHS(O)2-R8, -NHC(O)NH-R8, -NHC(S)NH-R8, -COO-, -OS(O)2-R8;
[0053] R6 is selected from the following group: substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted 5-7 membered heterocycle containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted C5-C9 furanose group, substituted or unsubstituted C5-C9 pyranose group; the substitution means that one or more hydrogen or hydroxyl groups on the sugar ring are replaced by a substituent selected from the following group: hydrogen, deuterium, tritium, halogen, cyano, amino, nitro, thiol, aldehyde, carboxyl, benzyl, substituted or unsubstituted C1-C 12 Alkoxycarbonyl, substituted or unsubstituted C2-C 12 Alkylaminocarbonyl, substituted or unsubstituted C2-C 10 Acyl, sulfonyl, phosphoryl, C5-C9 furanosyl, C5-C9 pyranosyl.
[0054] In another preferred embodiment, the pentacyclic triterpene carbon glycoside compound is the compound described in the embodiment:
[0055] The second aspect of the present invention provides a method for preparing the compound according to the first aspect of the present invention, characterized in that the preparation method comprises the following scheme 1 or scheme 2:
[0056] Scheme 1: Using the compound of formula IIa as a raw material, through step a and optional steps b, c or d, to prepare the compound of formula II:
[0057]
[0058] Wherein, the definitions of each group are as described in the first aspect of the present invention;
[0059] Step a: Compound IV and compound III react to obtain the product of step a;
[0060] Step b: reducing the product of step a to obtain the product of step b;
[0061] Step c: performing an alkylation reaction on the product of step b to obtain the product of step c;
[0062] Step d: reacting the product of step c with Dess-Martin reagent to obtain a compound of formula II;
[0063] The structure of compound IV is:
[0064]
[0065] Scheme 2: Using the compound of formula IIIa as a raw material, through step a and optional steps b, c or d, to prepare the compound of formula III:
[0066]
[0067] The third aspect of the present invention provides a pharmaceutical composition, which contains a therapeutically effective amount of the compound of formula I as described in the first aspect of the present invention, its pharmaceutically acceptable salts, racemates, R-isomers and S-isomers, and one or more pharmaceutically acceptable carriers, excipients, adjuvants, auxiliary materials and / or diluents.
[0068] The fourth aspect of the present invention provides a use of the compounds of formula I and formula II as described in the first aspect of the present invention, their racemates, R-isomers, S-isomers or pharmaceutically acceptable salts in the preparation of drugs for treating or preventing metabolic diseases and viral diseases associated with diabetes; preferably, the disease is selected from the following group: diabetes, influenza, obesity, liver fibrosis, metabolic diseases, viral diseases.
[0069] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS
[0070] Figure 1 The OGTT experimental data of ICR mice A2, A4, A6, A10, A25, A43, A44, A47, and A67 are shown;
[0071] Figure 2 It was shown that A25 and A43 exhibited good glucose-lowering effects in vivo;
[0072] Figure 3The EC50 of A64 and the positive drug ANT777 and the effect of promoting GLP secretion in vitro are shown;
[0073] Figure 4 It is shown that the compound of the present invention exhibits the same virus inhibition rate and low cytotoxicity as the positive drug ribavirin, and is similar to the virus inhibition rate of the positive drug ribavirin, but has lower cytotoxicity than ribavirin;
[0074] Figure 5 The experimental data of affinity between A102, A104, A106, A108, A112, A114, A116, A117, A120, A121, A122, A123, A124, A125, A126, and A127 and SARS-Cov-2 N protein are shown;
[0075] Figure 6 The affinity experimental data of compounds A102, A114 and A116 to N protein are shown;
[0076] Figure 7 and Figure 8 Shows experimental data of A102, A104, A114, A117, A118, A119, A120, A121, A122, A123, A124, A125, A126, A127, A128, and A129 inhibiting SARS-Cov-2 virus replication
[0077] Fig. 9 , Fig.10 The results showed that the A104 compound had good PK properties in mice. DETAILED DESCRIPTION
[0078] The inventors, through extensive and in-depth research, unexpectedly discovered for the first time a class of pentacyclic triterpenoid carbon glycosides with novel structure and excellent performance having oral hypoglycemic activity or antiviral activity, and completed the present invention on this basis.
[0079] the term
[0080] In the present invention, the halogen is F, Cl, Br or I.
[0081] In the present invention, unless otherwise specified, the terms used have the general meanings well known to those skilled in the art.
[0082] In the present invention, the term "C1-C6 alkyl" refers to a straight or branched alkyl group having 1 to 6 carbon atoms, including but not limited to methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl and hexyl, etc.; preferably ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.
[0083] In the present invention, the term "C1-C6 alkoxy" refers to a straight or branched alkoxy group having 1 to 6 carbon atoms, including but not limited to methoxy, ethoxy, propoxy, isopropoxy, butoxy and the like.
[0084] In the present invention, the term "C2-C6 alkenyl" refers to a straight or branched alkenyl group having 2 to 6 carbon atoms and containing one double bond, including but not limited to ethenyl, propenyl, butenyl, isobutenyl, pentenyl and hexenyl.
[0085] In the present invention, the term "C2-C6 alkynyl" refers to a straight or branched alkynyl group having 2 to 6 carbon atoms and containing one triple bond, including but not limited to ethynyl, propynyl, butynyl, isobutynyl, pentynyl and hexynyl.
[0086] In the present invention, the term "C3-C10 cycloalkyl" refers to a cyclic alkyl group having 3 to 10 carbon atoms in the ring, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and cyclodecyl, etc. The terms "C3-C8 cycloalkyl", "C3-C7 cycloalkyl", and "C3-C6 cycloalkyl" have similar meanings.
[0087] In the present invention, the term "C3-C10 cycloalkenyl" refers to a cyclic alkenyl group having 3 to 10 carbon atoms in the ring, including but not limited to cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl and cyclodecyl, etc. The term "C3-C7 cycloalkenyl" has a similar meaning.
[0088] In the present invention, the term "C1-C12 alkoxycarbonyl" refers to an alkoxycarbonyl group having 1 to 12 carbon atoms in the alkyl chain, including but not limited to methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, benzyloxycarbonyl and the like.
[0089] In the present invention, the term "C1-C12 alkylaminocarbonyl" refers to an alkylaminocarbonyl group having 1 to 12 carbon atoms in the alkyl chain, including but not limited to methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, tert-butylaminocarbonyl, benzylaminocarbonyl, dimethylaminocarbonyl and the like.
[0090] In the present invention, the term "C5-C9 furanosyl" refers to a furanosyl group having 5 to 9 carbon atoms, wherein the 1-position of the sugar group is connected to the main chain, including but not limited to ribofuranosyl, deoxyribofuranosyl, galactofuranosyl and the like.
[0091] In the present invention, the term "C5-C9 pyranosyl" refers to a pyranosyl group having 5 to 9 carbon atoms, wherein position 1 of the saccharide group is connected to the main chain, including but not limited to pyranosyl glucopyranosyl, pyranosyl glucuronide, pyranosyl rhamnosyl, pyranosyl galactosyl, pyranosyl mannosyl, pyranosyl xylopyranosyl and the like.
[0092] In the present invention, the term "aromatic ring" or "aryl" has the same meaning, preferably "aryl" is "C6-C12 aryl" or "C6-C10 aryl". The term "C6-C12 aryl" refers to an aromatic ring group having 6 to 12 carbon atoms without heteroatoms in the ring, such as phenyl, naphthyl, etc. The term "C6-C10 aryl" has a similar meaning.
[0093] In the present invention, the term "aromatic heterocycle" or "heteroaryl" has the same meaning and refers to a heteroaromatic group containing one to multiple heteroatoms. The heteroatoms referred to here include oxygen, sulfur and nitrogen. For example, furanyl, thienyl, pyridyl, pyrazolyl, pyrrolyl, N-alkylpyrrolyl, pyrimidyl, pyrazinyl, imidazolyl, tetrazolyl, etc. The heteroaryl ring can be fused to an aryl, heterocyclic or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring. The heteroaryl group can be optionally substituted or unsubstituted.
[0094] In the present invention, the term "3-12 membered heterocyclic group" refers to a saturated or unsaturated 3-12 membered ring group containing 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen in the ring, such as dioxolanyl, etc. The term "3-7 membered heterocyclic group" has a similar meaning.
[0095] In the present invention, the term "substituted" refers to one or more hydrogen atoms on a specific group being replaced by a specific substituent. The specific substituent is a substituent described above, or a substituent appearing in the embodiments. Unless otherwise specified, a substituted group may have a substituent selected from a specific group at any substitutable site of the group, and the substituent may be the same or different at each position. A cyclic substituent, such as a heterocycloalkyl, may be connected to another ring, such as a cycloalkyl, to form a spiro bicyclic system, for example, two rings having a common carbon atom. It will be appreciated by those skilled in the art that the combinations of substituents contemplated by the present invention are those that are stable or chemically feasible. The substituents include, but are not limited to, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 cycloalkyl, 3- to 12-membered heterocyclic groups, aryl, heteroaryl, halogen, hydroxyl, carboxyl (-COOH), C1-8 aldehyde, C2-10 acyl, C2-10 ester, C1-C12 alkoxycarbonyl, amino, alkoxy, C1-10 sulfonyl, etc.
[0096] Pentacyclic triterpene glycosides
[0097] The present invention provides a pentacyclic triterpene carbon glycoside derivative compound having a structure shown in the following general formula I or general formula II, or its racemate, R-isomer, S-isomer, pharmaceutically acceptable salt or mixture thereof:
[0098]
[0099] in:
[0100] R1, R2 and R3 are each independently selected from the group consisting of hydrogen and methyl; R4 is selected from the group consisting of hydrogen and isopropenyl;
[0101] R5 is selected from the following group: hydrogen, deuterium, tritium, halogen, cyano, amino, nitro, hydroxyl, thiol, aldehyde, carboxyl, sulfonyl, phosphate, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-7 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted C1-C6 alkyl-phenyl, substituted or unsubstituted C3-C12 cycloalkyl, substituted or unsubstituted C2-C10 acyl, substituted or unsubstituted C2-C10 ester, substituted or unsubstituted C6-C10 aryloxy, substituted or unsubstituted C1-C6 amide;
[0102] R6 is selected from the group consisting of substituted or unsubstituted C5-C9 furanose, substituted or unsubstituted C5-C9 pyranose; the substitution refers to one or more hydrogen or hydroxyl groups on the sugar ring being replaced by a substituent selected from the group consisting of hydrogen, deuterium, tritium, halogen, cyano, amino, nitro, thiol, aldehyde, carboxyl, benzyl, substituted or unsubstituted C1-C12 alkoxycarbonyl, substituted or unsubstituted C1-C12 alkylaminocarbonyl, substituted or unsubstituted C2-C10 acyl, sulfonyl, phosphoryl, C5-C9 furanose, C5-C9 pyranose;
[0103] X is selected from the group consisting of -CHR9-, carbonyl;
[0104] R9 is selected from the group consisting of hydrogen, deuterium, tritium, halogen, cyano, amino, nitro, hydroxyl, and mercapto;
[0105] Ring A is selected from the following group: 6-membered saturated carbocyclic ring or unsaturated carbocyclic ring;
[0106] n is 1 or 2.
[0107]
[0108] in:
[0109] R1, R2 and R3 are each independently selected from the group consisting of hydrogen and methyl; R4 is selected from the group consisting of hydrogen and isopropenyl;
[0110] R7 is selected from the group consisting of substituted or unsubstituted C5-C9 furanose, substituted or unsubstituted C5-C9 pyranose; the substitution refers to one or more hydrogen or hydroxyl groups on the sugar ring being replaced by a substituent selected from the group consisting of hydrogen, deuterium, tritium, halogen, cyano, amino, nitro, thiol, aldehyde, carboxyl, benzyl, substituted or unsubstituted C1-C12 alkoxycarbonyl, substituted or unsubstituted C1-C12 alkylaminocarbonyl, substituted or unsubstituted C2-C10 acyl, sulfonyl, phosphoryl, C5-C9 furanose, C5-C9 pyranose;
[0111] Y is selected from the group consisting of -(CH2)mCHR9-, carbonyl;
[0112] m is 0 or 1.
[0113] R9 is selected from the group consisting of hydrogen, deuterium, tritium, halogen, cyano, amino, nitro, hydroxyl, and mercapto;
[0114] Z is selected from the group consisting of carbonyl, -CH(R8)-, =N-R8;
[0115] R8 is selected from the following group: hydrogen, deuterium, tritium, halogen, cyano, amino, nitro, hydroxyl, thiol, aldehyde, carboxyl, sulfonyl, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-7 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted C1-C6 alkyl-phenyl, substituted or unsubstituted C3-C12 cycloalkyl, substituted or unsubstituted C2-C10 acyl, substituted or unsubstituted C2-C10 ester, substituted or unsubstituted C6-C10 aryloxy, substituted or unsubstituted C1-C6 amide;
[0116] Ring A is selected from the following group: 6-membered saturated carbocyclic ring or unsaturated carbocyclic ring;
[0117] n is 1 or 2.
[0118] In a more preferred embodiment of the present invention, the compounds of the general formula I and the general formula II of the present invention are preferably the following specific compounds:
[0119]
[0120]
[0121]
[0122]
[0123]
[0124]
[0125]
[0126]
[0127]
[0128]
[0129]
[0130]
[0131]
[0132]
[0133]
[0134]
[0135]
[0136]
[0137]
[0138]
[0139]
[0140]
[0141]
[0142]
[0143]
[0144]
[0145]
[0146]
[0147]
[0148]
[0149]
[0150] Active ingredients
[0151] The compound of the present invention may be an acrylic acid derivative compound having a structure as shown in the following general formula I, or a racemate, R-isomer, S-isomer, pharmaceutically acceptable salt or a mixture thereof:
[0152]
[0153] The definitions of the various groups are the same as above.
[0154] The compounds of the present invention have asymmetric centers, chiral axes and chiral planes, and may exist in the form of racemates, R-isomers or S-isomers. Those skilled in the art can obtain R-isomers and / or S-isomers by resolving the racemates using conventional techniques.
[0155] The present invention provides pharmaceutically acceptable salts of compounds of formula I and formula II, specifically, conventional pharmaceutically acceptable salts formed by reacting compounds of formula I and formula II with inorganic acids or organic acids. For example, conventional pharmaceutically acceptable salts can be prepared by reacting the compounds of Formula I and Formula II with inorganic acids or organic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, aminosulfonic acid and phosphoric acid, and organic acids such as citric acid, tartaric acid, lactic acid, pyruvic acid, acetic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, naphthalenesulfonic acid, ethanesulfonic acid, naphthalene disulfonic acid, maleic acid, malic acid, malonic acid, fumaric acid, succinic acid, propionic acid, oxalic acid, trifluoroacetic acid, stearic acid, pamoic acid, hydroxymaleic acid, phenylacetic acid, benzoic acid, salicylic acid, glutamic acid, ascorbic acid, p-aminobenzenesulfonic acid, 2-acetoxybenzoic acid and isethionic acid; or sodium salts, potassium salts, calcium salts, aluminum salts or ammonium salts formed by the compounds of Formula I and Formula II with inorganic bases; or methylamine salts, ethylamine salts or ethanolamine salts formed by the compounds of Formula I and Formula II with organic bases.
[0156] Preparation method
[0157] Another aspect of the present invention provides a method for preparing the compounds represented by Formula I and Formula II, and the preparation method is carried out according to the following Scheme 1 and Scheme 2.
[0158] The compound of formula (I) can be prepared by the method shown in the following scheme 1
[0159] The structural formulae and R group designations used in the following schemes are used only in this section. Compounds of formula (III), (IV) and (V) are commercially available or can be synthesized using conventional techniques in the art.
[0160] Scenario 1:
[0161]
[0162] The definitions of the various groups are the same as above.
[0163] Step a: Compound IV and Compound III were added to a 0.1 mol / L solution of samarium diiodide in redistilled tetrahydrofuran at 0°C and reacted for 1 h under argon protection.
[0164] Step b: The product of the previous step was dissolved in a mixed solvent of ethyl acetate:methanol (1:1), Pd / C was added, and the mixture was reacted at 50° C. in a hydrogen environment for 12 h.
[0165] Step c: The product of the previous step was dissolved in CS2, followed by addition of NaH (60% oil mixture) and stirring at room temperature for 2 hours. Then CH3I was added to react overnight, and then purified by column chromatography, dissolved in ultra-dry toluene, AIBN and tri-n-butyltin hydride were added under stirring, and stirred under reflux for 4 hours.
[0166] Step d: The product of the previous step was dissolved in dichloromethane, and Dess-Martin reagent was added and stirred for 2 h.
[0167] The structure of compound IV is:
[0168]
[0169] Scenario 2:
[0170]
[0171] The definitions of the various groups are the same as above.
[0172] The definitions of steps a, b, c, and d are the same as those in Scheme 1.
[0173] Pharmaceutical compositions and methods of administration
[0174] Since the compounds of the present invention have excellent blood sugar lowering and influenza virus inhibiting activities, the compounds of the present invention and their various crystal forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates, and pharmaceutical compositions containing the compounds of the present invention as the main active ingredient can be used to treat, prevent and alleviate diseases related to high blood sugar and influenza virus.
[0175] The pharmaceutical composition of the present invention comprises a safe and effective amount of the compound of the present invention or a pharmacologically acceptable salt thereof and a pharmacologically acceptable excipient or carrier. Wherein "safe and effective amount" means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects. Usually, the pharmaceutical composition contains 1-2000 mg of the compound of the present invention per dose, and more preferably, contains 5-200 mg of the compound of the present invention per dose. Preferably, the "one dose" is a capsule or tablet.
[0176] "Pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with the compounds of the present invention and with each other without significantly reducing the efficacy of the compounds. Some examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as ), wetting agents (such as sodium lauryl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
[0177] There is no particular limitation on the administration of the compound or pharmaceutical composition of the present invention. Representative administrations include, but are not limited to, oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration.
[0178] Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia; (c) humectants, for example, glycerol; (d) disintegrants, for example, agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solubilizers, for example, paraffin; (f) absorption accelerators, for example, quaternary ammonium compounds; (g) wetting agents, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.
[0179] Solid dosage forms such as tablets, pills, capsules, pills and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifiers, and the release of the active compound or compounds in such compositions can be delayed in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. If necessary, the active compound can also be formed into microencapsulated form with one or more of the above-mentioned excipients.
[0180] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage form may contain an inert diluent conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide and oils, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances.
[0181] Besides these inert diluents, the composition may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweeteners, flavoring agents, and perfumes.
[0182] Suspensions, in addition to the active compounds, may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methanol and agar, or mixtures of these substances, and the like.
[0183] Compositions for parenteral injection may include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
[0184] Dosage forms for topical administration of the compounds of the invention include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required.
[0185] The compounds of the present invention may be administered alone or in combination with other pharmaceutically acceptable compounds.
[0186] When using the pharmaceutical composition, a safe and effective amount of the compound of the present invention is applied to a mammal (such as a human) in need of treatment, wherein the dosage during administration is a pharmaceutically effective dosage, and for a person weighing 60 kg, the daily dosage is usually 1 to 2000 mg, preferably 5 to 500 mg. Of course, the specific dosage should also take into account factors such as the route of administration and the health status of the patient, which are all within the skill range of a skilled physician.
[0187] The main advantages of the present invention include the following:
[0188] The present invention provides a pentacyclic triterpene carbon glycoside derivative compound represented by general formula I or a pharmaceutically acceptable salt, racemate, R-isomer or S-isomer or a mixture thereof.
[0189] The invention also provides a method for preparing the compound.
[0190] The present invention also provides the use of the above-mentioned pentacyclic triterpene carbon glycoside derivative compounds or their pharmaceutically acceptable salts, racemates, R-isomers or S-isomers or mixtures thereof in the preparation of drugs for treating or preventing metabolic diseases such as diabetes, hyperlipidemia, etc.
[0191] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended only to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods for the unrecorded specific conditions in the following examples are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are weight percentages and weight parts.
[0192] Unless otherwise specified, the experimental materials and reagents used in the following examples can be obtained from commercial channels.
[0193] The present invention will be further illustrated in the following examples. These examples are only used to illustrate the present invention, but are not intended to limit the present invention in any way.
[0194] Example 1 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyloleanolic acid-3-(1'R)-(hydroxy)methyl-2",3",4",6"-O-tetrabenzyl-β-D-pyranoglucoside (A1)
[0195]
[0196] Compound (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid (100.0 mg, 0.18 mmol) and 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside (207.7 mg, 0.36 mmol) were dissolved in redistilled 15 mL tetrahydrofuran. Under argon protection, 0.1 mol / L tetrahydrofuran solution of samarium diiodide (15 mL, 1.5 mmol) was added at 0°C and stirred for 1 hour. After the reaction was completed as monitored by TLC, saturated ammonium chloride was added to quench the reaction, and the reaction was extracted with dichloromethane. The organic layers were combined and washed with saturated sodium chloride solution. The organic layers were dried over anhydrous sodium sulfate and concentrated. The crude product was purified by column chromatography to obtain the target product A1 (152 mg, 78%). 1H NMR (600MHz, CDCl3) δ7.40–7.08(m,26H),5.29(t,J=3.4Hz,1H),5.05(dt,J=16.2,11.9Hz,3H),4.95(d,J=11.0Hz,1H),4.83(dd,J=19.7,1 1.0Hz,2H),4.74(d,J=11.2Hz,1H),4.65–4.47(m,3H),4.01(d,J=5.8Hz,1H),3.78(t,J=8.9Hz,1H),3.68(s,1H),3.66–3.62(m,1H),3.58(t ,J=9.1Hz,1H),3.39(dt,J=9.7,3.0Hz,1H),3.31(dd,J=9.2,6.7Hz,1H),2.89(dd,J=13.6,4.0Hz,1H),1.98(td,J=13.5,3.9Hz,1H),1.87–1 .76(m,2H),1.26(s,3H),1.12(s,3H),0.94(s,3H),0.91(d,J=1.5Hz,4H),0.89(s,3H),0.85(s,3H),0.61(s,3H).LRMS(ESI):1083.66[M+H] + .
[0197] Example 2 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-pyranoglucoside (A2)
[0198]
[0199] Compound (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid (100.0 mg, 0.18 mmol) and 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside (207.7 mg, 0.36 mmol) were dissolved in redistilled 15 mL tetrahydrofuran. Under argon protection, 0.1 mol / L samarium diiodide tetrahydrofuran solution (15 mL, 1.5 mmol) was added at 0°C and stirred for 1 hour. After the reaction was completed as monitored by TLC, saturated ammonium chloride was added to quench the reaction, and the reaction was extracted with dichloromethane. The organic layers were combined and washed with saturated sodium chloride solution. The organic layers were dried over anhydrous sodium sulfate and concentrated. The crude product was purified by column chromatography to obtain 152 mg A1. It was then dissolved in ethyl acetate:methanol (15 mL:15 mL), 30 mg Pd / C was added in a hydrogen environment, and the mixture was reacted at 50° C. for 12 h. The target product A2 (70 mg, 79%) was then obtained by column chromatography. 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):631.43[MH] - .
[0200] Example 3 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyloleanolic acid-3-(1'R)-(hydroxy)methyl-2",3",4",6"-O-tetrabenzyl-β-D-pyranoglucoside (A3)
[0201] The (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyl-3-formyloleanolic acid, and the remaining raw materials, reagents and preparation method were the same as those in Example 1 to obtain A3 (yield 85%). 1H NMR (600MHz, CDCl3) δ7.40–7.08(m,26H),5.29(t,J=3.4Hz,1H),5.05(dt,J=16.2,11.9Hz,3H),4.95(d,J=11.0Hz,1H),4.83(dd,J=19.7,1 1.0Hz,2H),4.74(d,J=11.2Hz,1H),4.65–4.47(m,3H),4.01(d,J=5.8Hz,1H),3.78(t,J=8.9Hz,1H),3.68(s,1H),3.66–3.62(m,1H),3.58(t ,J=9.1Hz,1H),3.39(dt,J=9.7,3.0Hz,1H),3.31(dd,J=9.2,6.7Hz,1H),2.89(dd,J=13.6,4.0Hz,1H),1.98(td,J=13.5,3.9Hz,1H),1.87–1 .76(m,2H),1.26(s,3H),1.12(s,3H),0.94(s,3H),0.91(d,J=1.5Hz,4H),0.89(s,3H),0.85(s,3H),0.61(s,3H).LRMS(ESI):1083.66[M+H] + .
[0202] Example 4 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-pyranoglucoside (A4)
[0203] (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (3R,5S,8R,9R,10S,14R,17R,18S)-3-formyloleanolic acid. The remaining raw materials, reagents and preparation method were the same as those in Example 2 to obtain A4 (yield 74%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):631.43[MH] - .
[0204] Example 5 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyloleanolic acid-3-methyl-2", 3", 4", 6"-O-tetrabenzyl-β-D-pyranoglucoside (A5)
[0205]
[0206] Compound (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid (66.7 mg, 0.12 mmol) and 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside (138.5 mg, 0.24 mmol) were dissolved in redistilled 15 mL tetrahydrofuran. Under argon protection, 0.1 mol / L tetrahydrofuran solution of samarium diiodide (15 mL, 1.5 mmol) was added at 0°C and stirred for 1 hour. After the reaction was completed as monitored by TLC, saturated ammonium chloride was added to quench the reaction, and the reaction was extracted with dichloromethane. The organic layers were combined and washed with saturated sodium chloride solution. The organic layers were dried over anhydrous sodium sulfate and concentrated. The crude product was purified by column chromatography to obtain 152 mg of A1. It was then dissolved in 10 mL CS2, followed by the addition of NaH (15 mg, 0.37 mmol, 60% oil mixture) and stirred at room temperature for 2 hours. CH3I (31 μL, 0.50 mmol) was then added to react overnight. After the reaction was completed by TLC monitoring, saturated ammonium chloride was added to quench the reaction, extracted with dichloromethane, the organic layers were combined, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, concentrated, and the crude product was subjected to column chromatography to obtain intermediate A. Intermediate A and AIBN (23 mg, 0.14 mmol) were dissolved in 20 mL ultra-dry toluene, tri-n-butyltin hydride (0.12 mL, 0.45 mmol) was added under stirring, stirred under reflux for 4 hours, the reaction was completed by TLC monitoring, concentrated, and the target product A5 (64 mg, 65%) was obtained by column chromatography.
[0207] 1H NMR (600MHz, CDCl3) δ7.40–7.08(m,26H),5.29(t,J=3.4Hz,1H),5.05(dt,J=16.2,11.9Hz,3H),4.95(d,J=11.0Hz,1H),4.83(dd,J=19.7,1 1.0Hz,2H),4.74(d,J=11.2Hz,1H),4.65–4.47(m,3H),4.01(d,J=5.8Hz,1H),3.78(t,J=8.9Hz,1H),3.68(s,1H),3.66–3.62(m,1H),3.58(t ,J=9.1Hz,1H),3.39(dt,J=9.7,3.0Hz,1H),3.31(dd,J=9.2,6.7Hz,1H),2.89(dd,J=13.6,4.0Hz,1H),1.98(td,J=13.5,3.9Hz,1H),1.87–1 .76(m,2H),1.26(s,3H),1.12(s,3H),0.94(s,3H),0.91(d,J=1.5Hz,4H),0.89(s,3H),0.85(s,3H),0.61(s,3H).LRMS(ESI):1067.67[M+H] + .
[0208] Example 6 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-methyl-β-D-pyranoglucoside (A6)
[0209]
[0210] Compound (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid (66.7 mg, 0.12 mmol) and 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside (138.5 mg, 0.24 mmol) were dissolved in redistilled 15 mL tetrahydrofuran. Under argon protection, 0.1 mol / L tetrahydrofuran solution of samarium diiodide (15 mL, 1.5 mmol) was added at 0°C and stirred for 1 hour. After the reaction was completed as monitored by TLC, saturated ammonium chloride was added to quench the reaction, and the reaction was extracted with dichloromethane. The organic layers were combined and washed with saturated sodium chloride solution. The organic layers were dried over anhydrous sodium sulfate and concentrated. The crude product was purified by column chromatography to obtain A1. It was then dissolved in 10mL CS2, followed by the addition of NaH (15mg, 0.37mmol, 60% oil mixture) and stirred at room temperature for 2 hours. Then CH3I (31μL, 0.50mmol) was added to react overnight. After the reaction was completed by TLC monitoring, saturated ammonium chloride was added to quench the reaction, extracted with dichloromethane, the organic layers were combined, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, concentrated, and the crude product was subjected to column chromatography to obtain intermediate A. Intermediate A and AIBN (23mg, 0.14mmol) were dissolved in 20mL ultra-dry toluene, tri-n-butyltin hydride (0.12mL, 0.45mmol) was added under stirring, stirred under reflux for 4 hours, the reaction was completed by TLC monitoring, concentrated, and 64mg A5 was obtained by column chromatography. It was then dissolved in ethyl acetate:methanol (15mL:15mL), 13mg Pd / C was added in a hydrogen environment, and the reaction was carried out at 50°C for 12h, and then the target product A6 (27mg, 75%) was obtained by column chromatography.
[0211] 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):615.43[MH] - .
[0212] Example 7 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyloleanolic acid-3-methyl-2", 3", 4", 6"-O-tetrabenzyl-β-D-pyranoglucoside (A7)
[0213] The (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyl-3-formyloleanolic acid, and the remaining raw materials, reagents and preparation method were the same as those in Example 5 to obtain A7 (yield 67%). 1 H NMR (600MHz, CDCl3) δ7.40–7.08(m,26H),5.29(t,J=3.4Hz,1H),5.05(dt,J=16.2,11.9Hz,3H),4.95(d,J=11.0Hz,1H),4.83(dd,J=19.7,1 1.0Hz,2H),4.74(d,J=11.2Hz,1H),4.65–4.47(m,3H),4.01(d,J=5.8Hz,1H),3.78(t,J=8.9Hz,1H),3.68(s,1H),3.66–3.62(m,1H),3.58(t ,J=9.1Hz,1H),3.39(dt,J=9.7,3.0Hz,1H),3.31(dd,J=9.2,6.7Hz,1H),2.89(dd,J=13.6,4.0Hz,1H),1.98(td,J=13.5,3.9Hz,1H),1.87–1 .76(m,2H),1.26(s,3H),1.12(s,3H),0.94(s,3H),0.91(d,J=1.5Hz,4H),0.89(s,3H),0.85(s,3H),0.61(s,3H).LRMS(ESI):1067.67[M+H] + .
[0214] Example 8 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-methyl-β-D-pyranoglucoside (A8)
[0215] The (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid, and the remaining raw materials, reagents and preparation method were the same as those in Example 6 to obtain A8 (yield 71%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):615.43[MH] - .
[0216] Example 9 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyloleanolic acid-3-carbonyl-2", 3", 4", 6"-O-tetrabenzyl-β-D-pyranoglucoside (A9)
[0217]
[0218] Compound (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid (66.7 mg, 0.12 mmol) and 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside (138.5 mg, 0.24 mmol) were dissolved in redistilled 15 mL tetrahydrofuran. Under argon protection, 0.1 mol / L tetrahydrofuran solution of samarium diiodide (15 mL, 1.5 mmol) was added at 0°C and stirred for 1 hour. After the reaction was completed as monitored by TLC, saturated ammonium chloride was added to quench the reaction, and the reaction was extracted with dichloromethane. The organic layers were combined and washed with saturated sodium chloride solution. The organic layers were dried over anhydrous sodium sulfate and concentrated. The crude product was purified by column chromatography to obtain 152 mg of A1. It was then dissolved in 10 mL of dichloromethane, and then Dess-Martin reagent (76 mg, 0.18 mmol) was added and stirred at room temperature for 2 hours. After the reaction was completed by TLC monitoring, saturated sodium thiosulfate was added to quench the reaction, and dichloromethane was extracted. The organic layers were combined, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and concentrated. The crude product was subjected to column chromatography to obtain the target product A9 (90 mg, 90%). 1H NMR (600MHz, CDCl3) δ7.40–7.08(m,26H),5.29(t,J=3.4Hz,1H),5.05(dt,J=16.2,11.9Hz,3H),4.95(d,J=11.0Hz,1H),4.83(dd,J=19.7,1 1.0Hz,2H),4.74(d,J=11.2Hz,1H),4.65–4.47(m,3H),4.01(d,J=5.8Hz,1H),3.78(t,J=8.9Hz,1H),3.68(s,1H),3.66–3.62(m,1H),3.58(t ,J=9.1Hz,1H),3.39(dt,J=9.7,3.0Hz,1H),3.31(dd,J=9.2,6.7Hz,1H),2.89(dd,J=13.6,4.0Hz,1H),1.98(td,J=13.5,3.9Hz,1H),1.87–1 .76(m,2H),1.26(s,3H),1.12(s,3H),0.94(s,3H),0.91(d,J=1.5Hz,4H),0.89(s,3H),0.85(s,3H),0.61(s,3H).LRMS(ESI):1081.65[M+H] + .
[0219] Example 10 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-carbonyl-β-D-pyranoglucoside (A10)
[0220] Compound (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid (66.7 mg, 0.12 mmol) and 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside (138.5 mg, 0.24 mmol) were dissolved in redistilled 15 mL tetrahydrofuran. Under argon protection, 0.1 mol / L tetrahydrofuran solution of samarium diiodide (15 mL, 1.5 mmol) was added at 0°C and stirred for 1 hour. After the reaction was completed as monitored by TLC, saturated ammonium chloride was added to quench the reaction, and the reaction was extracted with dichloromethane. The organic layers were combined and washed with saturated sodium chloride solution. The organic layers were dried over anhydrous sodium sulfate and concentrated. The crude product was purified by column chromatography to obtain A1. It was then dissolved in 10 mL of dichloromethane, and then Dess-Martin reagent (76 mg, 0.18 mmol) was added and stirred at room temperature for 2 hours. After the reaction was completed by TLC monitoring, saturated sodium thiosulfate was added to quench the reaction, extracted with dichloromethane, the organic layers were combined, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and concentrated. The crude product was subjected to column chromatography to obtain 90 mg A9. It was then dissolved in ethyl acetate: methanol (15 mL: 15 mL), 13 mg Pd / C was added in a hydrogen atmosphere, and the reaction was carried out at 50°C for 12 hours, and then the target product A10 (38 mg, 73%) was obtained by column chromatography.
[0221] 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):629.41[MH] - .
[0222] Example 11 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyloleanolic acid-3-carbonyl-2", 3", 4", 6"-O-tetrabenzyl-β-D-pyranoglucoside (A11)
[0223] The (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid, and the remaining raw materials, reagents and preparation method were the same as those in Example 9 to obtain A11 (yield 89%). 1 H NMR (600MHz, CDCl3) δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3 Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,21 H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):1081.65[M+H] + .
[0224] Example 12 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-carbonyl-β-D-pyranoglucoside (A12)
[0225] The (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid, and the remaining raw materials, reagents and preparation method were the same as those in Example 10 to obtain A12 (yield 91%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):629.41[MH] - .
[0226] Example 13 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-galactopyranoside (A13)
[0227] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A13 (yield 77%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):631.43[MH] - .
[0228] Example 14 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-galactopyranoside (A14)
[0229] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A14 (yield 74%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):631.43[MH] - .
[0230] Example 15 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-methyl-β-D-galactopyranoside (A15)
[0231] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside, and the remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A15 (yield 63%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):615.43[MH] - .
[0232] Example 16 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-methyl-β-D-galactopyranoside (A16)
[0233] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid, and the remaining raw materials, reagents and preparation method were the same as those in Example 6 to obtain A16 (yield 74%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):615.43[MH] - .
[0234] Example 17 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-3-carbonyl-β-D-galactopyranoside (A17)
[0235] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside, and the remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A17 (yield 81%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):629.41[MH] - .
[0236] Example 18 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-carbonyl-β-D-galactopyranoside (A18)
[0237] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid, and the remaining raw materials, reagents and preparation method were the same as those in Example 10 to obtain A18 (yield 86%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):629.41[MH] - .
[0238] Example 19 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'S)-(hydroxy)methyl-α-D-mannopyranoside (A19)
[0239] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-α-D-pyranose glucosinolate. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A19 (yield 73%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):631.43[MH] - .
[0240] Example 20 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'S)-(hydroxy)methyl-α-D-mannopyranoside (A20)
[0241] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-α-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A20 (yield 62%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):631.43[MH] - .
[0242] Example 21 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-methyl-α-D-mannopyranoside (A21)
[0243] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-α-D-pyranose glucoside, and the remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A21 (yield 65%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):615.43[MH] - .
[0244] Example 22 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-methyl-α-D-mannopyranoside (A22)
[0245] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-α-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A22 (yield 64%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):615.43[MH] - .
[0246] Example 23 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-3-carbonyl-α-D-mannopyranoside (A23)
[0247] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-α-D-pyranose glucoside, and the remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A23 (yield 91%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):629.41[MH] - .
[0248] Example 24 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-carbonyl-α-D-mannopyranoside (A24)
[0249] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-α-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A24 (yield 86%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):629.41[MH] - .
[0250] Example 25 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-pyranoglucopyranoside (A25)
[0251] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A25 (yield 77%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):645.41[MH] - .
[0252] Example 26 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-pyranoglucopyranoside (A26)
[0253] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A26 (yield 72%). 1 HNMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3 Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88( dd,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m, 21H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):645.41[MH] - .
[0254] Example 27 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-methyl-β-D-pyranoglucopyranoside (A27)
[0255] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucopyranose glucosinolate, and the remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A27 (yield 65%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):629.41[MH] - .
[0256] Example 28 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-methyl-β-D-pyranoglucopyranoside (A28)
[0257] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A28 (yield 65%). 1 HNMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3 Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88( dd,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m, 21H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):629.41[MH] - .
[0258] Example 29 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-3-carbonyl-β-D-pyranoglucopyranoside (A29)
[0259] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucopyranose, and the remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A29 (yield 89%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):643.39[MH] - .
[0260] Example 30 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-3-carbonyl-β-D-pyranoglucopyranoside (A30)
[0261] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A30 (yield 88%). 1HNMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3 Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88( dd,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m, 21H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):643.39[MH] - .
[0262] Example 31 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'R)-(hydroxy)methyl-6"-deoxy-β-D-pyranoglucoside (A31)
[0263] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-6-deoxy-β-D-pyranose glucosinolate. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A31 (yield 67%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):615.43[MH] - .
[0264] Example 32 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'R)-(hydroxy)methyl-6"-deoxy-β-D-pyranoglucoside (A32)
[0265] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-6-deoxy-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A32 (yield 78%). 1 HNMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3 Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88( dd,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m, 21H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):615.43[MH] - .
[0266] Example 33 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-methyl-6"-deoxy-β-D-pyranoglucoside (A33)
[0267] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-6-deoxy-β-D-pyranose glucoside, and the remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A33 (yield 68%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):599.44[MH] - .
[0268] Example 34 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-methyl-6"-deoxy-β-D-pyranoglucoside (A34)
[0269] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-6-deoxy-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A34 (yield 65%). 1 HNMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3 Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88( dd,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m, 21H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):599.44[MH] - .
[0270] Example 35 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-3-carbonyl-6"-deoxy-β-D-pyranoglucoside (A35)
[0271] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-6-deoxy-β-D-pyranose glucoside, and the remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A35 (yield 86%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):613.42[MH] - .
[0272] Example 36 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-carbonyl-6"-deoxy-β-D-pyranoglucoside (A36)
[0273] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-6-deoxy-β-D-pyranose glucoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A36 (yield 85%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):613.42[MH] - .
[0274] Example 37 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-xylopyranoside (A37)
[0275] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A37 (yield 77%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):601.42[MH] - .
[0276] Example 38 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-xylopyranoside (A38)
[0277] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A38 (yield 78%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):601.42[MH] - .
[0278] Example 39 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-methyl-β-D-xylopyranoside (A39)
[0279] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and the remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A39 (yield 69%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):585.42[MH] - .
[0280] Example 40 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-methyl-β-D-xylopyranoside (A40)
[0281] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A40 (yield 66%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):585.42[MH] - .
[0282] Example 41 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-3-carbonyl-β-D-xylopyranoside (A41)
[0283] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and the remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A41 (yield 88%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):599.40[MH] - .
[0284] Example 42 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-3-carbonyl-β-D-xylopyranoside (A42)
[0285] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A42 (yield 81%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):599.40[MH] - .
[0286] Example 43 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'S)-(hydroxy)methyl-α-L-rhamnopyranoside (A43)
[0287] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-α-D-pyranose glucosinolate. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A43 (yield 75%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):615.43[MH] - .
[0288] Example 44 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'S)-(hydroxy)methyl-α-L-rhamnopyranoside (A44)
[0289] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-α-D-pyranose glucoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A44 (yield 71%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):615.43[MH] - .
[0290] Example 45 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'S)-methyl-α-L-rhamnopyranoside (A45)
[0291] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-α-D-pyranose rhamnoside glucoside, and the remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A45 (yield 68%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):599.44[MH] - .
[0292] Example 46 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'S)-methyl-α-L-rhamnopyranoside (A46)
[0293] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-α-D-pyranose glucoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A46 (yield 66%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):599.44[MH] - .
[0294] Example 47 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-3-(1'S)-carbonyl-α-L-rhamnopyranoside (A47)
[0295] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-α-D-pyranose rhamnoside glucoside, and the remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A47 (yield 84%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):613.42[MH] - .
[0296] Example 48 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-3-(1'S)-carbonyl-α-L-rhamnopyranoside (A48)
[0297] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-α-D-pyranose glucoside, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A48 (yield 87%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):613.42[MH] - .
[0298] Example 49 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'S)-(hydroxy)methyl-α-L-fucopyranoside (A49)
[0299] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A49 (yield 72%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):615.43[MH] - .
[0300] Example 50 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'S)-(hydroxy)methyl-α-L-fucopyranoside (A50)
[0301] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A50 (yield 71%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):615.43[MH] - .
[0302] Example 51 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'S)-methyl-α-L-fucopyranoside (A51)
[0303] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and the remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A51 (yield 69%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):599.44[MH] - .
[0304] Example 52 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'S)-methyl-α-L-fucopyranoside (A52)
[0305] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A52 (yield 61%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):599.44[MH] - .
[0306] Example 53 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-3-(1'S)-carbonyl-α-L-pyranofucoside (A53)
[0307] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and the remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A53 (yield 86%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):613.42[MH] - .
[0308] Example 54 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-3-(1'S)-carbonyl-α-L-fucopyranoside (A54)
[0309] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A54 (yield 82%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):613.42[MH] - .
[0310] Example 55 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'R)-(hydroxy)methyl-6"-deoxy-6"-fluoro-β-D-pyranoglucoside (A55)
[0311] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-6-deoxy-6-fluoro-β-D-pyranose glucosinolate. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A55 (yield 72%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):633.42[MH] - .
[0312] Example 56 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'R)-(hydroxy)methyl-6"-deoxy-6"-fluoro-β-D-pyranoglucoside (A56)
[0313] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-6-deoxy-6-fluoro-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A56 (yield 68%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):633.42[MH] - .
[0314] Example 57 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-methyl-6"-deoxy-6"-fluoro-β-D-pyranoglucoside (A57)
[0315] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-6-deoxy-6-fluoro-β-D-pyranose glucosinolate, and the remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A57 (yield 65%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):617.43[MH] - .
[0316] Example 58 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-methyl-6"-deoxy-6"-fluoro-β-D-pyranoglucoside (A58)
[0317] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-6-deoxy-6-fluoro-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A58 (yield 66%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):617.43[MH]- .
[0318] Example 59 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-3-carbonyl-6"-deoxy-6"-fluoro-β-D-pyranoglucoside (A59)
[0319] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-6-deoxy-6-fluoro-β-D-pyranose glucosinolate, and the remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A59 (yield 86%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):631.41[MH] - .
[0320] Example 60 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-carbonyl-6"-deoxy-6"-fluoro-β-D-pyranoglucoside (A60)
[0321] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-6-deoxy-6-fluoro-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A60 (yield 89%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):631.41[MH] - .
[0322] Example 61 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-xylopyranose (1→3)-β-D-pyranoglucopyranosyl (A61)
[0323] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose xylose (1→3)-β-D-pyranose glucosinolate. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A61 (yield 70%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):777.45[MH] - .
[0324] Example 62 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-xylopyranose (1→3)-β-D-pyranoglucopyranosyl (A62)
[0325] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose (1→3)-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A62 (yield 68%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):777.45[MH] - .
[0326] Example 63 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-methyl-β-D-xylopyranose (1→3)-β-D-pyranoglucopyranosyl (A63)
[0327] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose xylose (1→3)-β-D-pyranoglucuronide, and the remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A63 (yield 69%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H), 1.06–0.93 (m, 12H), 0.90–0.82 (m, 6H), 0.81 (d, J = 11.4Hz, 1H). LRMS (ESI): 761.46 [MH].
[0328] Example 64 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-methyl-β-D-xylopyranose (1→3)-β-D-pyranoglucopyranoside (A64)
[0329] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose (1→3)-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A64 (yield 70%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):761.46[MH]- .
[0330] Example 65 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-carbonyl-β-D-xylopyranose (1→3)-β-D-pyranoglucopyranosyl (A65)
[0331] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose xylose (1→3)-β-D-pyranoglucuronide, and the remaining raw materials, reagents and preparation method were the same as those in Example 10 to obtain A65 (yield 86%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):775.43[MH] - .
[0332] Example 66 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-3-carbonyl-β-D-xylopyranose (1→3)-β-D-pyranoglucopyranosyl (A66)
[0333] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose (1→3)-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A66 (yield 89%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):775.43[MH] - .
[0334] Example 67 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S, 19S, 20R)-ursolic acid-3-(1'R)-(hydroxy)methyl-β-D-pyranoglucopyranoside (A67)
[0335] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3S,5S,8R,9R,10S,14R,17R,18S,19S,20R)-28-O-benzyl-3-formyl ursolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A67 (yield 72%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):645.41[MH]- .
[0336] Example 68 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S, 19S, 20R)-ursolic acid-3-(1'R)-(hydroxy)methyl-β-D-pyranoglucopyranoside (A68)
[0337] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S,19S,20R)-28-O-benzyl-3-formyl ursolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A68 (yield 68%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):645.41[MH] - .
[0338] Example 69 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S, 19S, 20R)-ursolic acid-3-methyl-β-D-pyranoglucopyranoside (A69)
[0339] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3S,5S,8R,9R,10S,14R,17R,18S,19S,20R)-28-O-benzyl-3-formyl ursolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A69 (yield 68%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):613.42[MH] - .
[0340] Example 70 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S, 19S, 20R)-ursolic acid-3-methyl-β-D-pyranoglucopyranoside (A70)
[0341] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S,19S,20R)-28-O-benzyl-3-formyl ursolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A70 (yield 63%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):613.42[MH] - .
[0342] Example 71 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S, 19S, 20R)-Ursolic acid-3-carbonyl-β-D-pyranoglucopyranoside (A71)
[0343] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (3S,5S,8R,9R,10S,14R,17R,18S,19S,20R)-28-O-benzyl-3-formylursolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A71 (yield 85%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):627.40[MH]- .
[0344] Example 72 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S, 19S, 20R)-ursolic acid-3-carbonyl-β-D-pyranoglucopyranoside (A72)
[0345] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3R,5S,8R,9R,10S,14R,17R,18S,19S,20R)-28-O-benzyl-3-formyl ursolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A72 (yield 89%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):627.40[MH] - .
[0346] Example 73 (3S, 5S, 8R, 9R, 10S, 13R, 14R, 17S, 18R, 19R)-betulinic acid-3-(1'R)-(hydroxy)methyl-β-D-pyranoglucopyranoside (A73)
[0347] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3S,5S,8R,9R,10S,13R,14R,17S,18R,19R)-28-O-benzyl-3-formyl betulinic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A73 (yield 71%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):645.41[MH] - .
[0348] Example 74 (3S, 5S, 8R, 9R, 10S, 13R, 14R, 17S, 18R, 19R)-betulinic acid-3-(1'R)-(hydroxy)methyl-β-D-pyranoglucopyranoside (A74)
[0349] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (3R,5S,8R,9R,10S,13R,14R,17S,18R,19R)-28-O-benzyl-3-formylbetulic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A74 (yield 69%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):645.41[MH] - .
[0350] Example 75 (3S, 5S, 8R, 9R, 10S, 13R, 14R, 17S, 18R, 19R)-betulinic acid-3-methyl-β-D-pyranoglucopyranoside (A75)
[0351] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (3S,5S,8R,9R,10S,13R,14R,17S,18R,19R)-28-O-benzyl-3-formylbetulic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A75 (yield 70%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):613.42[MH]- .
[0352] Example 76 (3S, 5S, 8R, 9R, 10S, 13R, 14R, 17S, 18R, 19R)-betulinic acid-3-methyl-β-D-pyranoglucopyranoside (A76)
[0353] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (3R,5S,8R,9R,10S,13R,14R,17S,18R,19R)-28-O-benzyl-3-formylbetulic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A76 (yield 65%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):613.42[MH] - .
[0354] Example 77 (3S, 5S, 8R, 9R, 10S, 13R, 14R, 17S, 18R, 19R)-Betulinic acid-3-carbonyl-β-D-pyranoglucopyranoside (A77)
[0355] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3S,5S,8R,9R,10S,13R,14R,17S,18R,19R)-28-O-benzyl-3-formyl betulinic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A77 (yield 88%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):627.40[MH] - .
[0356] Example 78 (3S, 5S, 8R, 9R, 10S, 13R, 14R, 17S, 18R, 19R)-betulinic acid-3-carbonyl-β-D-pyranoglucopyranoside (A78)
[0357] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (3R,5S,8R,9R,10S,13R,14R,17S,18R,19R)-28-O-benzyl-3-formylbetulic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A78 (yield 89%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):627.40[MH] - .
[0358] Example 79 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-28-β-D-pyranoglucopyranosyl acid (A79)
[0359] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A79 (yield 71%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):613.38[MH] - .
[0360] Example 80 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(1'R)-(hydroxy)methyl-β-D-pyranoglucuronide (A80)
[0361] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A80 (yield 69%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):615.40[MH] - .
[0362] Example 81 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-methyl-β-D-pyranoglucopyranoside (A81)
[0363] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A81 (yield 90%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):599.40[MH] - .
[0364] Example 82 (5S, 8R, 9R, 10S, 14R, 17R, 18S19S, 20R)-3-Carbonyl ursolic acid-28-β-D-pyranoglucopyranosyl acid (A82)
[0365] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S19S,20R)-3-carbonyl-17-formyl ursolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A82 (yield 72%). 1 HNMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3 Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88( dd,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m, 21H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):613.38[MH] - .
[0366] Example 83 (5S, 8R, 9R, 10S, 14R, 17R, 18S19S, 20R)-3-Carbonyl ursolic acid-17-(1'R)-(hydroxy)methyl-β-D-pyranoglucopyranoside (A83)
[0367] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S19S,20R)-3-carbonyl-17-formyl ursolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A83 (yield 69%). 1 HNMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3 Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88( dd,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m, 21H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):615.40[MH] - .
[0368] Example 84 (5S, 8R, 9R, 10S, 14R, 17R, 18S, 19S, 20R)-3-Carbonyl ursolic acid-17-methyl-β-D-pyranoglucopyranoside (A84)
[0369] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S19S,20R)-3-carbonyl-17-formyl ursolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A84 (yield 86%). 1 HNMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3 Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88( dd,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m, 21H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):599.40[MH] - .
[0370] Example 85 (5S, 8R, 9R, 10S, 13R, 14R, 17S, 18R, 19R)-3-Carbonylbetulinic acid-28-β-D-pyranoglucopyranoside (A85)
[0371] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,13R,14R,17S,18R,19R)-3-carbonyl-17-formylbetulic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A85 (yield 74%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):613.38[MH] - .
[0372] Example 86 (5S, 8R, 9R, 10S, 13R, 14R, 17S, 18R, 19R)-3-Carbonylbetulinic acid-17-(1'R)-(hydroxy)methyl-β-D-pyranoglucuronide (A86)
[0373] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,13R,14R,17S,18R,19R)-3-carbonyl-17-formylbetulic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A86 (yield 71%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):615.40[MH]- .
[0374] Example 87 (5S, 8R, 9R, 10S, 13R, 14R, 17S, 18R, 19R)-3-Carbonylbetulinic acid-17-methyl-β-D-pyranoglucopyranoside (A87)
[0375] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,13R,14R,17S,18R,19R)-3-carbonyl-17-formylbetulic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A87 (yield 85%). 1 HNMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3 Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88( dd,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m, 21H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):599.40[MH] - .
[0376] Example 88 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-ethyloleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-pyranoglucuronide (A88)
[0377] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-ethyl-3-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A88 (yield 71%). 1 HNMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3 Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88( dd,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m, 21H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):673.44[MH] - .
[0378] Example 89 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-allyl oleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-pyranoglucuronide (A89)
[0379] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-allyl-3-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A89 (yield 70%). 1HNMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3 Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88( dd,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m, 21H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):685.44[MH] - .
[0380] Example 90 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-(O-ethyl)carboxymethyloleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-pyranoglucuronide (A90)
[0381] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-(O-ethyl)carboxymethyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A90 (yield 71%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):731.44[MH] - .
[0382] Example 91 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-acetoxyoleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-pyranoglucopyranoside (A91)
[0383] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-acetoxy-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A91 (yield 69%). 1 HNMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3 Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88( dd,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m, 21H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):703.41[MH]- .
[0384] Example 92 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-hydroxyethyl oleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-pyranoglucopyranoside (A92)
[0385] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-hydroxyethyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A92 (yield 71%). 1 HNMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3 Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88( dd,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m, 21H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):689.43[MH] - .
[0386] Example 93 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-(N-methyl)aminoethyl oleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-pyranoglucuronide (A93)
[0387] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-(N-methyl)aminoethyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A93 (yield 69%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):702.47[MH] - .
[0388] Example 94 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-(N, N-diethyl)aminoethyl oleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-pyranoglucuronide (A94)
[0389] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-(N,N-diethyl)aminoethyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A94 (yield 68%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):744.51[MH] - .
[0390] Example 95 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-hydroxybut-2"'-ynyloleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-pyranoglucuronide (A95)
[0391] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-hydroxybutan-2"'-ynyl-3-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A95 (yield 62%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):713.43[MH] - .
[0392] Example 96 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-cyclohexyloleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-pyranoglucuronide (A96)
[0393] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-cyclohexyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A96 (yield 69%). 1 HNMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3 Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88( dd,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m, 21H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):727.49[MH]- .
[0394] Example 97 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-(O-methyl)carboxymethylaminooleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-pyranoglucuronide (A97)
[0395] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-(O-methyl)carboxymethylamino-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A97 (yield 73%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):716.45[MH] - .
[0396] Example 98 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-Carboxymethylaminooleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-pyranoglucuronide (A98)
[0397] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-carboxymethylamino-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A98 (yield 62%). 1 HNMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3 Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88( dd,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m, 21H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):702.43[MH] - .
[0398] Example 99 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-(N, N-diethyl)aminopropylaminooleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-pyranoglucuronide (A99)
[0399] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-(N,N-diethyl)aminopropylamino-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A99 (yield 66%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):757.54[MH] - .
[0400] Example 100 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-(N-acetyl)aminopropylaminooleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-pyranoglucuronide (A100)
[0401] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-(N-acetyl)aminopropylamino-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A100 (yield 65%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):743.49[MH] - .
[0402] Example 101 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-(N, N-diethyl)aminohexylaminooleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-pyranoglucuronide (A101)
[0403] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-(N,N-diethyl)aminohexylamino-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A101 (yield 71%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):799.59[MH] - .
[0404] Example 102 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-(N-acetyl)aminohexylaminooleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-pyranoglucuronide (A102)
[0405] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-(N-acetyl)aminohexylamino-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A102 (yield 68%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):785.54[MH] - .
[0406] Example 103 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-(N-ethyl)aminohexylaminooleanolic acid-3-(1'R)-(hydroxy)methyl-β-D-pyranoglucuronide (A103)
[0407] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-(N-ethyl)aminohexylamino-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A103 (yield 69%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):771.56[MH] - .
[0408] Example 104 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-(pyrazol-1″-yl)methyloleanolic acid-3-(1′R)-(hydroxy)methyl-β-D-pyranoglucopyranoside (A104)
[0409] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-(pyrazol-1-yl)methyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A104 (yield 65%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):725.45[MH] - .
[0410] Example 105 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-(piperidin-1″-yl)methyloleanolic acid-3-(1′R)-(hydroxy)methyl-β-D-pyranoglucuronide (A105)
[0411] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-(piperidin-1-yl)methyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A105 (yield 70%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):756.51[MH] - .
[0412] Example 106 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-(morpholin-4″-yl)methyloleanolic acid-3-(1′R)-(hydroxy)methyl-β-D-pyranoglucopyranoside (A106)
[0413] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-(morpholin-4-yl)methyl-3-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A106 (yield 67%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):758.49[MH] - .
[0414] Example 107 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-3-(1'R)-fluoromethyl-β-D-pyranoglucopyranoside (A107)
[0415]
[0416] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside, and Dess-Martin reagent was replaced with DAST. The remaining raw materials, reagents and preparation methods were the same as those in Example 10, and the product A107 was obtained (yield 65%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):647.40[MH] - .
[0417] Example 108 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'R)-(hydroxy)methyl-28-(1"R)-(hydroxy)methyl-β-D-dipyranoglucuronide (A108)
[0418] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (3S,5S,8R,9R,10S,14R,17R,18S)-3,17-diformyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A108 (yield 62%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,4H),3.46(dd,J=20.4,9.3H z,4H),3.38(s,2H),3.35–3.31(m,2H),3.23(d,J=9.5Hz,2H),3.11(d,J=9.5Hz,2H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):807.46[MH] - .
[0419] Example 109 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'R)-(hydroxy)methyl-6"-O-methyl-β-D-pyranoglucopyranoside (A109)
[0420] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-6-O-methyl-β-D-pyranoglucoside. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A109 (yield 71%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):659.42[MH] - .
[0421] Example 110 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'R)-(hydroxy)methyl-6"-O-n-butyl-β-D-pyranoglucopyranoside (A110)
[0422] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-6-O-n-butyl-β-D-pyranoglucoside. The remaining raw materials, reagents and preparation method were the same as those in Example 2 to obtain A110 (yield 71%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):701.47[MH] - .
[0423] Example 111 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'R)-(hydroxy)methyl-6"-O-isobutyl-β-D-pyranoglucopyranoside (A111)
[0424] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-6-O-isobutyl-β-D-pyranoglucoside. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A111 (yield 61%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):701.47[MH] - .
[0425] Example 112 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'R)-(hydroxy)methyl-6"-O-benzyl-β-D-pyranoglucuronide (A112)
[0426] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-6-O-benzyl-β-D-pyranoglucoside. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A112 (yield 68%). 1H NMR(500MHz,MeOD)δ7.32(m,5H),5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J= 20.4,9.3Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H), 2.88(dd,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05( m,21H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):735.46[MH] - .
[0427] Example 113 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'R)-(hydroxy)methyl-6"-O-(1-fluoroacetyl)-β-D-pyranoglucopyranoside (A113)
[0428] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-6″-O-(1-fluoroacetyl)-β-D-pyranoglucopyranose. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A113 (yield 72%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):658.44[MH] - .
[0429] Example 114 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-3-(1'R)-(hydroxy)methyl-6"-methylamino-β-D-pyranoglucopyranoside (A114)
[0430] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-6-methylamino-β-D-pyranoglucoside. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A114 (yield 72%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):658.44[MH] - .
[0431] Example 115 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'R)-(hydroxy)methyl-6"-n-butylamino-β-D-pyranoglucopyranoside (A115)
[0432] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-6-n-butylamino-β-D-pyranoglucoside. The remaining raw materials, reagents and preparation method were the same as those in Example 2 to obtain A115 (yield 70%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):600.49[MH] - .
[0433] Example 116 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'R)-(hydroxy)methyl-6"-isobutylamino-β-D-pyranoglucopyranoside (A116)
[0434] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-6-isobutylamino-β-D-pyranoglucoside. The remaining raw materials, reagents and preparation method were the same as those in Example 2 to obtain A116 (yield 80%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):700.49[MH] - .
[0435] Example 117 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-3-(1'R)-(hydroxy)methyl-6"-benzylamino-β-D-pyranoglucopyranoside (A117)
[0436] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-6-benzylamino-β-D-pyranoglucoside. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A117 (yield 82%). 1 H NMR(500MHz,MeOD)δ7.33(m,5H),5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J= 20.4,9.3Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H), 2.88(dd,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05( m,21H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):734.47[MH] - .
[0437] Example 118 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'R)-(hydroxy)methyl-6"-dimethylamino-β-D-pyranoglucopyranoside (A118)
[0438] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-6-dimethylamino-β-D-pyranoglucoside. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A118 (yield 72%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):672.46[MH] - .
[0439] Example 119 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'R)-(hydroxy)methyl-6"-(1-fluoroethylamino)-β-D-pyranoglucopyranoside (A119)
[0440] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-6-(1-fluoroethylamino)-β-D-pyranoglucoside. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A119 (yield 72%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):672.46[MH] - .
[0441] Example 120 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-3-(1'R)-(hydroxy)methyl-5"-cyano-β-D-xylopyranoside (A120)
[0442] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced with 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-5-cyano-β-D-pyranose glucosinolate. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A120 (yield 78%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):626.41[MH] - .
[0443] Example 121 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(1'S)-(hydroxy)methyl-β-D-mannopyranoside (A121)
[0444] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A121 (yield 69%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):603.42[M+H] + .
[0445] Example 122 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-17-(1'S)-(hydroxy)methyl-β-D-mannopyranoside (A122)
[0446] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-hydroxy-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A122 (yield 73%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):605.43[M+H] + .
[0447] Example 123 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-methoxyoleanolic acid-17-(1'S)-(hydroxy)methyl-β-D-mannopyranoside (A123)
[0448] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-methoxy-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A123 (yield 70%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):619.45[M+H] + .
[0449] Example 124 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-(4-fluorocyclohexyloxy)oleanolic acid-17-(1'S)-(hydroxy)methyl-β-D-mannopyranoside (A124)
[0450] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-(4-fluorocyclohexyloxy)-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A124 (yield 72%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):705.50[M+H] + .
[0451] Example 125 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-acetoxyoleanolic acid-17-(1'S)-(hydroxy)methyl-β-D-mannopyranoside (A125)
[0452] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-acetoxy-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A125 (yield 77%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):647.44[M+H] + .
[0453] Example 126 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-fluoroacetoxyoleanolic acid-17-(1'S)-(hydroxy)methyl-β-D-mannopyranoside (A126)
[0454] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-fluoroacetoxy-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A126 (yield 72%). 1 HNMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3 Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):665.44[M+H]+ .
[0455] Example 127 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-(4-fluorophenylacetyloxy)oleanolic acid-17-(1'S)-(hydroxy)methyl-β-D-mannopyranoside (A127)
[0456] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-(4-fluorophenylacetyloxy)-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A127 (yield 71%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):727.45[M+H] + .
[0457] Example 128 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-(4-trifluoromethylbenzenesulfonyloxy)oleanolic acid-17-(1'S)-(hydroxy)methyl-β-D-mannopyranoside (A128)
[0458] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-(4-trifluoromethylbenzenesulfonyloxy)-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A128 (yield 69%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):813.41[M+H] + .
[0459] Example 129 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-(2,3,5,6-tetrafluorobenzamido)oleanolic acid-17-(1'S)-(hydroxy)methyl-β-D-mannopyranoside (A129)
[0460] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-(2,3,5,6-tetrafluorobenzamide)-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A129 (yield 76%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):780.44[M+H] + .
[0461] Example 130 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-(4-trifluoromethylbenzenesulfonylamino)oleanolic acid-17-(1'S)-(hydroxy)methyl-β-D-mannopyranoside (A130)
[0462] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-(4-trifluoromethylbenzenesulfonylamido)-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A130 (yield 68%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):812.43[M+H] + .
[0463] Example 131 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-oxime oleanolic acid-17-(1'S)-(hydroxy)methyl-β-D-mannopyranoside (A131)
[0464] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-oximino-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A131 (yield 69%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):618.43[M+H] + .
[0465] Example 132 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-methylhydrazine oleanolic acid-17-(1'S)-(hydroxy)methyl-β-D-pyranoside (A132)
[0466] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-methylhydrazono-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A132 (yield 79%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):631.46[M+H] + .
[0467] Example 133 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-phenylhydrazone oleanolic acid-17-(1'S)-(hydroxy)methyl-β-D-pyranoside (A133)
[0468] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-phenylhydrazine-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A133 (yield 76%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):693.48[M+H] + .
[0469] Example 134 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-(4-fluorophenylureido)oleanolic acid-17-(1'S)-(hydroxy)methyl-β-D-mannopyranoside (A134)
[0470] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-(4-fluorophenylureido)-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A134 (yield 68%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):741.48[M+H] + .
[0471] Example 135 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-(4-fluorophenylthioureido)oleanolic acid-17-(1'S)-(hydroxy)methyl-β-D-mannopyranoside (A135)
[0472] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-(4-fluorophenylthioureido)-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A135 (yield 71%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):757.45[M+H] + .
[0473] Example 136 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Formyloleanolic acid-17-(1'S)-(hydroxy)methyl-β-D-mannopyranoside (A136)
[0474] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-formyl-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A136 (yield 72%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):617.43[M+H] +.
[0475] Example 137 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-(3-fluorocyclobutylthio)oleanolic acid-17-(1'S)-(hydroxy)methyl-β-D-mannopyranoside (A137)
[0476] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-(3-fluorocyclobutylthio)-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A137 (yield 73%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):693.45[M+H] + .
[0477] Example 138 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-phenylthiooleanolic acid-17-(1'S)-(hydroxy)methyl-β-D-mannopyranoside (A138)
[0478] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-phenylthio-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A138 (yield 69%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):697.44[M+H] + .
[0479] Example 139 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-28-β-D-mannopyranoside (A139)
[0480] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A139 (yield 71%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):601.40[M+H] + .
[0481] Example 140 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(1'S)-fluoromethyl-β-D-mannopyranoside (A140)
[0482] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-fluoromethyl-17-formyl oleanolic acid, and Dess-Martin reagent was replaced by DAST. The remaining raw materials, reagents and preparation methods were the same as those in Example 10, and the product A140 was obtained (yield 67%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):645.41[M+H]+ .
[0483] Example 141 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-methyl-β-D-mannopyranoside (A141)
[0484] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A141 (yield 80%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):587.42[M+H] + .
[0485] Example 142 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(1'S)-(hydroxy)methyl-2",3",4",6"-O-tetraacetyl-β-D-mannopyranoside (A142)
[0486] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetraacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A142 (yield 67%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):771.46[M+H] + .
[0487] Example 143 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-17-(1'S)-(hydroxy)methyl-2",3",4",6"-O-tetraacetyl-β-D-mannopyranoside (A143)
[0488] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetraacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-hydroxy-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A143 (yield 66%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):773.48[M+H] + .
[0489] Example 144 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-methyl-2", 3", 4", 6"-O-tetraacetyl-β-D-pyranoside (A144)
[0490] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetraacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A144 (yield 70%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):755.47[M+H]+ .
[0491] Example 145 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(2'S)-(hydroxy)ethyl-β-D-mannopyranoside (A145)
[0492] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A145 (yield 68%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):617.43[M+H] + .
[0493] Example 146 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(2'S)-(hydroxy)ethyl-2",3",4",6"-O-tetraacetyl-β-D-mannopyranoside (A146)
[0494] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetraacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A146 (yield 68%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):685.48[M+H] + .
[0495] Example 147 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyl ursolic acid-17-(2'S)-(hydroxy)ethyl-2",3",4",6"-O-tetraacetyl-β-D-mannopyranoside (A147)
[0496] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetraacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl ursolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A147 (yield 69%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):685.48[M+H] + .
[0497] Example 148 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonylbetulinic acid-17-(2'S)-(hydroxy)ethyl-2",3",4",6"-O-tetraacetyl-β-D-mannopyranoside (A148)
[0498] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetraacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl betulinic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A148 (yield 71%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):685.48[M+H] + .
[0499] Example 149 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(1'R)-(hydroxy)methyl-β-D-xylopyranoside (A149)
[0500] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-tribenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A149 (yield 71%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):573.41[M+H] + .
[0501] Example 150 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-methyl-β-D-xylopyranoside (A150)
[0502] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-tribenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A150 (yield 77%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):557.41[M+H] + .
[0503] Example 151 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-17-(1'R)-(hydroxy)methyl-β-D-xylopyranoside (A151)
[0504] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-tribenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-hydroxy-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A151 (yield 73%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):575.42[M+H] + .
[0505] Example 152 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(1'R)-(hydroxy)methyl-2",3",4"-O-triacetyl-β-D-xylopyranoside (A152)
[0506] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-triacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A152 (yield 69%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):698.44[M+H]+ .
[0507] Example 153 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-methyl-2", 3", 4"-O-triacetyl-β-D-xylopyranoside (A153)
[0508] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-triacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A153 (yield 74%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):683.44[M+H] + .
[0509] Example 154 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(2'R)-(hydroxy)ethyl-2",3",4"-O-triacetyl-β-D-xylopyranoside (A154)
[0510] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-triacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A154 (yield 70%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):713.46[M+H] + .
[0511] Example 155 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyl ursolic acid-17-(2'R)-(hydroxy)ethyl-2",3",4"-O-triacetyl-β-D-xylopyranoside (A155)
[0512] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-triacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl ursolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A155 (yield 69%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):713.46[M+H] + .
[0513] Example 156 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonylbetulinic acid-17-(2'R)-(hydroxy)ethyl-2",3",4"-O-triacetyl-β-D-xylopyranoside (A156)
[0514] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-triacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl betulinic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A156 (yield 71%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):713.46[M+H]+ .
[0515] Example 157 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(1'R)-(hydroxy)methyl-β-D-galactopyranoside (A157)
[0516] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A157 (yield 70%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):603.42[M+H] + .
[0517] Example 158 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-methyl-β-D-galactopyranoside (A158)
[0518] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A158 (yield 76%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):587.42[M+H] + .
[0519] Example 159 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-17-(1'R)-(hydroxy)methyl-β-D-galactopyranoside (A159)
[0520] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-hydroxy-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A159 (yield 74%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,1H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):605.43[M+H] + .
[0521] Example 160 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(1'R)-(hydroxy)methyl-2",3",4",6"-O-tetraacetyl-β-D-galactopyranoside (A160)
[0522] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside was replaced by 2,3,4,6-O-tetraacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A160 (yield 70%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):771.46[M+H] + .
[0523] Example 161 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-methyl-2", 3", 4", 6"-O-tetraacetyl-β-D-galactopyranoside (A161)
[0524] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside was replaced by 2,3,4,6-O-tetraacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A161 (yield 74%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):755.47[M+H]+ .
[0525] Example 162 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(2'R)-(hydroxy)ethyl-β-D-galactopyranoside (A162)
[0526] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A162 (yield 68%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):617.43[M+H] + .
[0527] Example 163 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(2'R)-(hydroxy)ethyl-2",3",4",6"-O-tetraacetyl-β-D-galactopyranoside (A163)
[0528] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside was replaced by 2,3,4,6-O-tetraacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A163 (yield 72%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):785.48[M+H] + .
[0529] Example 164 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyl ursolic acid-17-(2'R)-(hydroxy)ethyl-2",3",4",6"-O-tetraacetyl-β-D-galactopyranoside (A164)
[0530] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside was replaced by 2,3,4,6-O-tetraacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl ursolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A164 (yield 68%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):785.48[M+H] + .
[0531] Example 165 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonylbetulinic acid-17-(2'R)-(hydroxy)ethyl-2",3",4",6"-O-tetraacetyl-β-D-galactopyranoside (A165)
[0532] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside was replaced by 2,3,4,6-O-tetraacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinoside, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-aldehyde oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl betulinic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A165 (yield 74%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):785.48[M+H] + .
[0533] Example 166 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(1'R)-(hydroxy)methyl-α-L-rhamnopyranoside (A166)
[0534] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced by 2,3,4-O-tribenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A166 (yield 74%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):587.42[M+H] + .
[0535] Example 167 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-methyl-α-L-rhamnopyranoside (A167)
[0536] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-tribenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A167 (yield 74%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):571.43[M+H] + .
[0537] Example 168 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-17-(1'R)-(hydroxy)methyl-α-L-rhamnopyranoside (A168)
[0538] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced by 2,3,4-O-tribenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-hydroxy-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A168 (yield 75%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,1H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):589.44[M+H] + .
[0539] Example 169 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(1'R)-(hydroxy)methyl-2",3",4"-O-triacetyl-α-L-rhamnopyranoside (A169)
[0540] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced by 2,3,4-O-triacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A169 (yield 73%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):713.46[M+H]+ .
[0541] Example 170 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-methyl-2", 3", 4"-O-triacetyl-α-L-rhamnopyranoside (A170)
[0542] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced by 2,3,4-O-triacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A170 (yield 74%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):697.46[M+H] + .
[0543] Example 171 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(2'R)-(hydroxy)ethyl-α-L-rhamnopyranoside (A171)
[0544] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced by 2,3,4-O-tribenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A171 (yield 70%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):601.44[M+H] + .
[0545] Example 172 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carboxyloleanolic acid-17-(2'R)-(hydroxy)ethyl-2",3",4"-O-triacetyl-α-L-rhamnopyranoside (A172)
[0546] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced by 2,3,4-O-triacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A172 (yield 72%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):727.47[M+H] + .
[0547] Example 173 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carboxyl ursolic acid-17-(2'R)-(hydroxy)ethyl-2",3",4"-O-triacetyl-α-L-rhamnopyranoside (A173)
[0548] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced by 2,3,4-O-triacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl ursolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A173 (yield 69%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):727.47[M+H]+ .
[0549] Example 174 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonylbetulinic acid-17-(2'R)-(hydroxy)ethyl-2",3",4"-O-triacetyl-α-L-rhamnopyranoside (A174)
[0550] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-triacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl betulinic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A174 (yield 71%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):727.47[M+H] + .
[0551] Example 175 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-17-(1'R)-(hydroxy)methyl-β-D-pyranoglucopyranoside (A175)
[0552] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-tribenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-hydroxy-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A175 (yield 70%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,1H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):619.41[M+H] + .
[0553] Example 176 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-carbonyl-2", 3", 4"-O-triacetyl-β-D-pyranoglucopyranoside (A176)
[0554] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-triacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A176 (yield 70%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,1H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):741.41[M+H] + .
[0555] Example 177 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(1'R)-(hydroxy)methyl-2",3",4"-O-triacetyl-β-D-pyranoglucopyranoside (A177)
[0556] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-triacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A177 (yield 71%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):743.43[M+H]+ .
[0557] Example 178 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-methyl-2", 3", 4"-O-triacetyl-β-D-pyranoglucopyranoside (A178)
[0558] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-triacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A178 (yield 69%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):727.43[M+H] + .
[0559] Example 179 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(2'R)-(hydroxy)ethyl-β-D-pyranoglucopyranoside (A179)
[0560] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-tribenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A179 (yield 70%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):631.41[M+H] + .
[0561] Example 180 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(2'R)-(hydroxy)ethyl-2",3",4"-O-triacetyl-β-D-pyranoglucuronide (A180)
[0562] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-triacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A180 (yield 69%). 1HNMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3 Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):757.44[M+H] + .
[0563] Example 181 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyl ursolic acid-17-(2'R)-(hydroxy)ethyl-2",3",4"-O-triacetyl-β-D-pyranoglucopyranoside (A181)
[0564] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-triacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl ursolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A181 (yield 77%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):757.44[M+H]+ .
[0565] Example 182 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonylbetulinic acid-17-(2'R)-(hydroxy)ethyl-2",3",4"-O-triacetyl-β-D-pyranoglucopyranoside (A182)
[0566] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-triacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl betulinic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A182 (yield 72%). 1 HNMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3 Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):757.44[M+H] + .
[0567] Example 183 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(1'R)-(hydroxy)methyl-6"-deoxy-6"-fluoro-β-D-pyranoglucoside (A183)
[0568] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced by 2,3,4-O-tribenzyl-1-(pyridin-1-yl)sulfonyl-6-deoxy-6-fluoro-β-D-pyranose glucoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A183 (yield 70%). 1 HNMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3 Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):605.41[M+H] + .
[0569] Example 184 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-methyl-6"-deoxy-6"-fluoro-β-D-pyranoglucoside (A184)
[0570] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-tribenzyl-1-(pyridin-1-yl)sulfonyl-6-deoxy-6-fluoro-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A184 (yield 71%). 1HNMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3 Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):589.42[M+H] + .
[0571] Example 185 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-oleanolic acid-17-(1'R)-(hydroxy)methyl-6"-deoxy-6"-fluoro-β-D-pyranoglucoside (A185)
[0572] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced by 2,3,4-O-tribenzyl-1-(pyridin-1-yl)sulfonyl-6-deoxy-6-fluoro-β-D-pyranose glucoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-hydroxy-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A185 (yield 75%). 1 HNMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3 Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88( dd,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m, 21H),1.06–0.93(m,1H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):607.43[M+H]+ .
[0573] Example 186 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(1'R)-(hydroxy)methyl-2",3",4"-O-triacetyl-6"-deoxy-6"-fluoro-β-D-pyranoglucoside (A186)
[0574] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-triacetyl-1-(pyridin-1-yl)sulfonyl-6-deoxy-6-fluoro-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A186 (yield 70%). 1 HNMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3 Hz,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):731.45[M+H] + .
[0575] Example 187 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-methyl-2", 3", 4"-O-triacetyl-6"-deoxy-6"-fluoro-β-D-pyranoglucoside (A187)
[0576] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-triacetyl-1-(pyridin-1-yl)sulfonyl-6-deoxy-6-fluoro-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A187 (yield 75%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):715.45[M+H] + .
[0577] Example 188 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(2'R)-(hydroxy)ethyl-6"-deoxy-6"-fluoro-β-D-pyranoglucoside (A188)
[0578] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced by 2,3,4-O-tribenzyl-1-(pyridin-1-yl)sulfonyl-6-deoxy-6-fluoro-β-D-pyranose glucoside, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-aldehyde oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A188 (yield 76%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):619.43[M+H] + .
[0579] Example 189 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(2'R)-(hydroxy)ethyl-2",3",4"-O-triacetyl-6"-deoxy-6"-fluoro-β-D-pyranoglucoside (A189)
[0580] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced by 2,3,4-O-triacetyl-1-(pyridin-1-yl)sulfonyl-6-deoxy-6-fluoro-β-D-pyranose glucoside, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-aldehyde oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A189 (yield 69%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):745.46[M+H] + .
[0581] Example 190 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyl ursolic acid-17-(2'R)-(hydroxy)ethyl-2",3",4"-O-triacetyl-6"-deoxy-6"-fluoro-β-D-pyranoglucopyranoside (A190)
[0582] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-triacetyl-1-(pyridin-1-yl)sulfonyl-6-deoxy-6-fluoro-β-D-pyranose glucosinolate, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-aldehyde oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl ursolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A190 (yield 67%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):745.46[M+H] + .
[0583] Example 191 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonylbetulinic acid-17-(2'R)-(hydroxy)ethyl-2",3",4"-O-triacetyl-6"-deoxy-6"-fluoro-β-D-pyranoglucoside (A191)
[0584] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-triacetyl-1-(pyridin-1-yl)sulfonyl-6-deoxy-6-fluoro-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-aldehyde oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl betulinic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A191 (yield 71%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):745.46[M+H] + .
[0585] Example 192 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(1'R)-(hydroxy)methyl-β-D-pyranoglucoside (A192)
[0586] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A192 (yield 70%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):603.42[M+H] + .
[0587] Example 193 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-methyl-β-D-pyranoglucoside (A193)
[0588] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A193 (yield 84%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):587.42[M+H] + .
[0589] Example 194 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-17-(1'R)-(hydroxy)methyl-β-D-pyranoglucoside (A194)
[0590] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-hydroxy-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A194 (yield 79%).1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,1H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):605.43[M+H] + .
[0591] Example 195 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(1'R)-(hydroxy)methyl-2",3",4",6"-O-tetraacetyl-β-D-pyranoglucoside (A195)
[0592] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced by 2,3,4,6-O-tetraacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A195 (yield 79%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):771.46[M+H] + .
[0593] Example 196 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-methyl-2", 3", 4", 6"-O-tetraacetyl-β-D-pyranoglucoside (A196)
[0594] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced by 2,3,4,6-O-tetraacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A196 (yield 78%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):755.47[M+H]+ .
[0595] Example 197 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(2'R)-(hydroxy)ethyl-β-D-pyranoglucoside (A197)
[0596] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced by 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside, (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A197 (yield 75%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):617.43[M+H] + .
[0597] Example 198 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(2'R)-(hydroxy)ethyl-2",3",4",6"-O-tetraacetyl-β-D-pyranoglucoside (A198)
[0598] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced by 2,3,4,6-O-tetraacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-aldehyde oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A198 (yield 72%). 1 H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):785.48[M+H] + .
[0599] Example 199 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyl ursolic acid-17-(2'R)-(hydroxy)ethyl-2",3",4",6"-O-tetraacetyl-β-D-pyranoglucoside (A199)
[0600] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside was replaced by 2,3,4,6-O-tetraacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucoside, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl ursolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A199 (yield 79%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):785.48[M+H] + .
[0601] Example 200 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonylbetulinic acid-17-(2'R)-(hydroxy)ethyl-2",3",4",6"-O-tetraacetyl-β-D-pyranoglucoside (A200)
[0602] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4,6-O-tetraacetyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate, and (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylmethyl betulinic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A200 (yield 77%). 1H NMR(500MHz,MeOD)δ5.28(s,1H),4.16(s,1H),3.79(d,J=2.0Hz,2H),3.46(dd,J=20.4,9.3H z,2H),3.38(s,1H),3.35–3.31(m,1H),3.23(d,J=9.5Hz,1H),3.11(d,J=9.5Hz,1H),2.88(d d,J=13.5,3.0Hz,1H),2.03(dd,J=13.5,10.3Hz,1H),1.93(d,J=7.1Hz,2H),1.86–1.05(m,2 1H),1.06–0.93(m,12H),0.90–0.82(m,6H),0.81(d,J=11.4Hz,1H).LRMS(ESI):785.48[M+H] + .
[0603] Example 201 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-28-β-D-pyranoglucoside (A201)
[0604] The compound (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-carbonyl-17-formyloleanolic acid. The remaining raw materials, reagents and preparation method were the same as those in Example 10 to obtain A201 (yield 72%). 1H NMR (500MHz, CDCl3) δ5.48 (d, J=5.9Hz, 1H), 5.33 (tdd, J=5.1, 1.8, 1.1Hz, 1H), 5.07 (d, J= 5.7Hz,1H),4.57(d,J=6.3Hz,1H),4.44(dd,J=8.8,2.6Hz,1H),4.19(t,J=4.5Hz,1H),3.7 1–3.58(m,3H),3.58(dt,J=7.7,3.5Hz,1H),3.58–3.49(m,1H),3.31(dddd,J=8.5,7.8,5. 8,1.8Hz,1H),2.48(ddd,J=12.5,6.5,4.0Hz,1H),2.40(ddd,J=12.5,6.6,4.0Hz,1H),2.1 7(tq,J=5.1,1.0Hz,1H),2.04(dddd,J=12.6,6.4,5.1,1.0Hz,1H),1.95–1.87(m,1H),1.9 1–1.84(m,1H),1.86–1.81(m,1H),1.84–1.78(m,2H),1.72–1.59(m,6H),1.62–1.48(m,3H ),1.51–1.41(m,1H),1.44–1.36(m,2H),1.40–1.33(m,1H),1.36–1.29(m,1H),1.15(s,2H ),1.08(t,J=1.6Hz,5H),0.99–0.92(m,6H),0.93(d,J=6.6Hz,5H).LRMS(ESI): 601.4[M+H] + .
[0605] Example 202 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyl ursolic acid-28-β-D-pyranoglucopyranoside (A202)
[0606] The compound (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-carbonyl-17-formylursolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A202 (yield 72%). 1H NMR (500MHz, CDCl3) δ5.53–5.46(m,2H),5.07(d,J=5.7Hz,1H),4.57(d,J=6.3Hz,1H) ,4.51(dd,J=8.8,2.6Hz,1H),4.19(t,J=4.5Hz,1H),3.71–3.58(m,3H),3.58(dt,J=7 .7,3.5Hz,1H),3.58–3.49(m,1H),3.31(dddd,J=8.4,7.8,5.8,1.8Hz,1H),2.48(ddd ,J=12.5,6.5,4.0Hz,1H),2.40(ddd,J=12.5,6.6,4.0Hz,1H),2.28–2.22(m,1H),2.0 6–1.91(m,2H),1.89–1.78(m,4H),1.77(ddd,J=12.5,7.7,5.2Hz,1H),1.73–1.57(m, 5H),1.60–1.54(m,1H),1.57–1.51(m,1H),1.48–1.41(m,1H),1.44–1.38(m,2H),1.4 1–1.35(m,1H),1.35(dtd,J=6.5,3.2,1.6Hz,1H),1.34–1.25(m,1H),1.20(s,2H),1. 08(t,J=1.6Hz,5H),0.99–0.90(m,9H),0.91(d,J=2.0Hz,2H).LRMS(ESI): 601.4[M+H] + .
[0607] Example 203 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyl ursolic acid-17-(1'R)-(hydroxy)methyl-β-D-pyranoglucoside (A203)
[0608] The compound (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-carbonyl-17-formylursolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A203 (yield 64%). 1H NMR (500MHz, CDCl3) δ5.47 (tdd, J=4.9, 1.7, 1.0Hz, 1H), 4.95 (d, J=5.3Hz, 1H), 4 .81(dd,J=11.0,5.7Hz,2H),4.61(d,J=6.2Hz,1H),4.20(t,J=4.5Hz,1H),4.00– 3.88(m,2H),3.72(dddd,J=8.8,7.9,6.1,2.8Hz,1H),3.70–3.65(m,1H),3.68–3 .55(m,4H),2.48(ddd,J=12.5,6.5,4.0Hz,1H),2.40(ddd,J=12.5,6.6,4.0Hz,1 H),2.06–1.86(m,4H),1.84(ddd,J=6.6,2.9,1.5Hz,1H),1.84–1.78(m,1H),1.7 1–1.64(m,1H),1.65(dd,J=3.9,1.6Hz,1H),1.66–1.54(m,4H),1.57–1.51(m,1H ),1.54–1.44(m,1H),1.47–1.39(m,2H),1.42–1.35(m,3H),1.37–1.32(m,1H),1 .35–1.25(m,1H),1.11–1.05(m,8H),0.99–0.88(m,11H).LRMS(ESI): 603.4[M+H] + .
[0609] Example 204 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-ursolic acid-17-(1'R)-(hydroxy)methyl-β-D-pyranoglucoside (A204)
[0610] The compound (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-17-formylursolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A204 (yield 50%). 1H NMR (500MHz, CDCl3) δ5.47 (tdd, J=4.9, 1.7, 1.0Hz, 1H), 4.95 (d, J=5.3Hz, 1H), 4.81 (dd, J=11 .0,5.7Hz,2H),4.61(d,J=6.2Hz,1H),4.20(t,J=4.5Hz,1H),4.00–3.88(m,2H),3.76–3.55(m ,6H),3.31–3.23(m,1H),3.00(d,J=10.8Hz,1H),2.01–1.86(m,4H),1.74–1.25(m,19H),1.09 (s,2H),0.97(d,J=1.5Hz,3H),0.95–0.90(m,9H),0.93–0.87(m,6H).LRMS(ESI): 605.4[M+H] + .
[0611] Example 205 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-ursolic acid-28-β-D-pyranoglucoside (A205)
[0612] The compound (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-17-formylursolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A205 (yield 50%). 1 H NMR (500MHz, CDCl3) δ5.53–5.46(m,2H),5.07(d,J=5.7Hz,1H),4.57(d,J=6.3H z,1H),4.51(dd,J=8.8,2.6Hz,1H),4.19(t,J=4.5Hz,1H),3.71–3.49(m,5H),3 .36–3.23(m,2H),3.00(d,J=10.8Hz,1H),2.28–2.22(m,1H),2.01–1.93(m,1H) ,1.89–1.24(m,20H),1.20(s,2H),0.99–0.87(m,16H).LRMS(ESI):603.4[M+H] + .
[0613] Example 206 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-28-β-D-pyranoglucoside (A206)
[0614] The compound (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (3S,5S,8R,9R,10S,14R,17R,18S)-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A206 (yield 50%). 1 H NMR (500MHz, CDCl3) δ5.48(d,J=5.9Hz,1H),5.33(tdd,J=5.1,1.8,1.1Hz,1H),5.07(d,J=5.7Hz,1H),4.57(d,J=6.3H z,1H),4.44(dd,J=8.8,2.6Hz,1H),4.19(t,J=4.5Hz,1H),3.71–3.58(m,3H),3.58(dt,J=7.7,3.5Hz,1H),3.58–3.49( m,1H),3.36–3.23(m,2H),3.00(d,J=10.8Hz,1H),2.17(tq,J=5.1,1.0Hz,1H),2.05(dddd,J=12.5,6.2,5.1,1.0Hz,1H ),1.96–1.78(m,3H),1.74–1.39(m,15H),1.42–1.27(m,4H),1.15(s,2H),0.99–0.87(m,17H).LRMS(ESI): 603.4[M+H] + .
[0615] Example 207 (3S, 5S, 8R, 9R, 10S, 13R, 14R, 17S, 18R, 19R)-betulinic acid-28-β-D-pyranoglucoside (A207)
[0616] The compound (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (3S,5S,8R,9R,10S,14R,17R,18S)-17-formylbetulic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A207 (yield 55%). 1H NMR (500MHz, CDCl3) δ5.48(d,J=5.9Hz,1H),5.07(d,J=5.7Hz,1H),4.83(h,J=1.6Hz,1H),4.67(h,J=1.5Hz, 1H),4.57(d,J=6.3Hz,1H),4.47(dd,J=8.8,2.5Hz,1H),4.19(t,J=4.5Hz,1H),3.72–3.49(m,5H),3.36–3.23 (m,2H),3.04–2.96(m,2H),1.82–1.48(m,22H),1.51–1.47(m,1H),1.50–1.43(m,1H),1.45–1.35(m,1H),1.3 1(ddq,J=6.8,4.0,1.5Hz,1H),1.18(ddp,J=7.4,4.4,1.5Hz,1H),0.99–0.91(m,11H),0.82(t,J=1.5Hz,3H). LRMS(ESI):603.4[M+H] + .
[0617] Example 208 (3S, 5S, 8R, 9R, 10S, 13R, 14R, 17S, 18R, 19R)-betulinic acid-17-(1'R)-(hydroxy)methyl-β-D-pyranoglucoside (A208)
[0618] The compound (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (3S,5S,8R,9R,10S,14R,17R,18S)-17-formylbetulic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A208 (yield 56%). 1H NMR(500MHz, CDCl3) δ4.95(d,J=5.1Hz,1H),4.84–4.79(m,2H),4.69(d,J=5.3Hz,1H),4.65(h,J=1.6Hz,1H),4.61(d,J=6.2Hz,1H) ,4.20(t,J=4.5Hz,1H),3.93(dddd,J=8.6,7.6,5.9,1.8Hz,1H),3.85(dddd,J=7.7,5.1,2.8Hz,1H),3.72(dddd,J=8.8,7.5,6.0,2.9 Hz,1H),3.71–3.64(m,1H),3.68–3.61(m,2H),3.64–3.58(m,1H),3.57(ddd,J=12.3,4.6,3.3Hz,1H),3.31–3.23(m,1H),2.18–2.0 9(m,1H),1.76–1.27(m,25H),1.18(ddp,J=7.4,4.4,1.5Hz,1H),0.99–0.90(m,11H),0.82(t,J=1.5Hz,3H).LRMS(ESI): 605.4[M+H] + .
[0619] Example 209 (5S, 8R, 9R, 10S, 13R, 14R, 17S, 18R, 19R)-3-Carbonylbetulinic acid-17-(1'R)-(hydroxy)methyl-β-D-pyranoglucoside (A209)
[0620] The compound (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-carbonyl-17-formylbetulic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A209 (yield 60%). 1 H NMR (500MHz, CDCl3) δ4.84–4.79(m,1H),4.71–4.59(m,1H),3.76–3.53(m,2H),2.53–2.41(m,1H),1.86–1.76(m,1H),1.73(q,J=1.4Hz, 1H),1.63–1.28(m,7H),1.13–1.05(m,2H),0.97(d,J=1.5Hz,1H),0.92(d,J=1.5Hz,1H),0.85(t,J=1.4Hz,1H).LRMS(ESI): 603.4[M+H] + .
[0621] Example 210 (5S, 8R, 9R, 10S, 13R, 14R, 17S, 18R, 19R)-3-Carbonylbetulinic acid-28-β-D-pyranoglucoside (A210)
[0622] The compound (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-carbonyl-17-formylbetulic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A210 (yield 51%). 1 H NMR (500MHz, CDCl3) δ5.48(d,J=5.9Hz,1H),5.07(d,J=5.7Hz,1H),4.83(h,J=1.6Hz,1H),4.67(h,J=1.5Hz,1H),4.57(d,J=6.3Hz,1H),4 .47(dd,J=8.8,2.5Hz,1H),4.19(t,J=4.5Hz,1H),3.72–3.49(m,5H),3.31(dddd,J=8.4,7.7,5.8,1.8Hz,1H),3.00(dddt,J=10.3,5.0,3. 3,1.6Hz,1H),2.53–2.41(m,2H),1.86–1.59(m,11H),1.62–1.57(m,1H),1.59–1.53(m,2H),1.51(ddddd,J=12.4,7.7,6.5,2.6,1.4Hz,7 H),1.50–1.40(m,3H),1.44–1.34(m,2H),1.13–1.05(m,7H),0.96(dd,J=12.7,1.5Hz,6H),0.85(t,J=1.4Hz,3H).LRMS(ESI): 601.4[M+H] + .
[0623] Example 211 (5S, 8R, 9R, 10S, 13R, 14R, 17S, 18R, 19R)-3-Carbonylbetulinic acid-17-methyl-β-D-pyranoglucoside (A211)
[0624] The compound (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-carbonyl-17-formylbetulic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A211 (yield 61%). 1H NMR(500MHz, CDCl3)δ4.85(d,J=5.9Hz,1H),4.83–4.78(m,2H),4.65(h,J=1.5Hz,1H) ,4.61(d,J=6.4Hz,1H),4.23–4.16(m,1H),3.88(ddtd,J=32.6,9.0,7.5,2.1Hz,2H),3 .73(dddd,J=8.8,7.7,6.2,2.2Hz,1H),3.70–3.63(m,2H),3.60–3.51(m,2H),2.53–2 .41(m,2H),2.23(dtq,J=7.0,5.3,1.7Hz,1H),1.96(dd,J=13.8,7.2Hz,1H),1.83(ddd ,J=5.7,2.8,1.4Hz,1H),1.83–1.76(m,1H),1.73(q,J=1.5Hz,3H),1.70–1.60(m,1H) ,1.63–1.57(m,1H),1.59–1.54(m,1H),1.57–1.44(m,10H),1.47–1.42(m,1H),1.44–1 .37(m,3H),1.40–1.33(m,1H),1.21(dd,J=6.9,5.6Hz,1H),1.13–1.05(m,7H),0.97( d,J=1.5Hz,3H),0.92(d,J=1.3Hz,3H),0.85(t,J=1.5Hz,3H).LRMS(ESI): 587.4[M+H] + .
[0625] Example 212 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyl ursolic acid-17-methyl-β-D-pyranoglucoside (A212)
[0626] The compound (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-carbonyl-17-formylursolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A212 (yield 57%). 1H NMR(500MHz, CDCl3)δ5.45(tdd,J=4.9,1.8,1.1Hz,1H),4.85(d,J=5.9Hz,1H),4.80(d,J=5.7Hz,1H),4.61(d,J=6.4Hz,1H),4.23–4.17(m,1H),3.96–3 .88(m,1H),3.84(dtd,J=9.3,7.0,2.3Hz,1H),3.73(dddd,J=8.9,7.9,6.3, 2.3Hz,1H),3.70–3.62(m,2H),3.62–3.51(m,2H),2.48(ddd,J=12.5,6.5,4. 0Hz,1H),2.40(ddd,J=12.5,6.6,4.0Hz,1H),2.07–2.01(m,1H),2.04–1.98 (m,1H),1.96(dddd,J=12.5,6.3,4.9,1.0Hz,1H),1.84(dddd,J=6.6,2.9,1.5 Hz,1H),1.84–1.78(m,1H),1.80–1.70(m,3H),1.70–1.20(m,15H),1.11–1. 05(m,9H),0.97(d,J=1.5Hz,3H),0.95–0.86(m,9H).LRMS(ESI):587.4[M+H] + .
[0627] Example 213 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-17-methyl-β-D-pyranoglucoside (A213)
[0628] The compound (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A213 (yield 56%). 1H NMR (500MHz, CDCl3) δ5.26(tdd,J=5.3,1.8,1.0Hz,1H),4.85(d,J=5.9Hz,1H),4.80(d,J=5.7Hz,1H),4.61(d,J=6.4Hz,1 H),4.23–4.17(m,1H),3.96–3.87(m,1H),3.84–3.70(m,2H),3.70–3.62(m,2H),3.62–3.51(m,2H),3.31–3.23(m,1H),3. 00(d,J=10.8Hz,1H),2.68(tq,J=4.8,1.0Hz,1H),2.03(dd,J=14.0,6.7Hz,1H),1.85(dddd,J=12.7,6.4,5.2,1.0Hz,1H) ,1.76(dddd,J=12.5,6.4,5.1,1.0Hz,1H),1.74–1.20(m,22H),1.09(s,2H),0.99–0.87(m,17H).LRMS(ESI):589.4[M+H] + .
[0629] Example 214 (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyl ursolic acid-17-methyl-β-D-pyranoglucoside (A214)
[0630] The compound (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-17-formylursolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A214 (yield 56%). 1H NMR (500MHz, CDCl3) δ5.45(tdd,J=5.0,1.8,1.1Hz,1H),4.85(d,J=5.9Hz,1H),4.80(d,J=5.7Hz,1H),4.61(d,J=6.4H z,1H),4.23–4.17(m,1H),3.96–3.88(m,1H),3.84(dtd,J=9.3,7.0,2.3Hz,1H),3.73(dddd,J=8.9,7.9,6.3,2.3Hz,1 H),3.70–3.62(m,2H),3.62–3.51(m,2H),3.31–3.23(m,1H),3.00(d,J=10.8Hz,1H),2.03(dd,J=13.9,7.0Hz,1H),2. 00–1.91(m,2H),1.80–1.20(m,23H),1.09(s,2H),0.97(d,J=1.5Hz,3H),0.95–0.86(m,14H).LRMS(ESI):589.4[M+H] + .
[0631] Example 215 (3S, 5S, 8R, 9R, 10S, 13R, 14R, 17S, 18R, 19R)-betulinic acid-17-methyl-β-D-pyranoglucoside (A215)
[0632] The compound (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-17-formylbetulic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 6 to obtain A215 (yield 48%). 1H NMR (500MHz, CDCl3) δ4.85(d,J=5.9Hz,1H),4.83–4.78(m,2H),4.65(h,J=1.5Hz,1H),4.61(d,J=6.4Hz,1H),4.23–4.16(m,1 H),3.88(ddtd,J=32.6,9.0,7.5,2.1Hz,2H),3.73(dddd,J=8.8,7.7,6.2,2.2Hz,1H),3.70–3.63(m,2H),3.60–3.51(m,2H), 3.31–3.23(m,1H),3.00(d,J=10.8Hz,1H),2.23(dtq,J=7.0,5.3,1.7Hz,1H),1.96(dd,J=13.8,7.2Hz,1H),1.76–1.33(m,24 H),1.31(ddq,J=6.8,4.1,1.5Hz,1H),1.24–1.15(m,2H),0.99–0.91(m,11H),0.82(t,J=1.5Hz,3H).LRMS(ESI): 589.4[M+H] + .
[0633] Example 216 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-28-β-D-pyranoglucoside (A216)
[0634] The compound (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A216 (yield 55%). 1H NMR (500MHz, CDCl3) δ5.48(d,J=5.9Hz,1H),5.33(tdd,J=5.1,1.8,1.1Hz,1H),5.07(d,J=5.7Hz,1H),4.57(d,J=6.2Hz, 1H),4.44(dd,J=8.8,2.6Hz,1H),4.19(t,J=4.5Hz,1H),3.67(ddd,J=10.9,3.9,2.8Hz,1H),3.67–3.61(m,1H),3.64–3. 49(m,3H),3.36–3.25(m,2H),3.00(d,J=10.8Hz,1H),2.17(tq,J=5.1,1.0Hz,1H),2.05(dddd,J=12.5,6.2,5.1,1.0Hz, 1H),1.96–1.79(m,3H),1.79–1.40(m,15H),1.43–1.27(m,4H),1.15(s,2H),0.99–0.88(m,17H).LRMS(ESI): 603.4[M+H] + .
[0635] Example 217 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-Oleanolic acid-17-(1'R)-(hydroxy)methyl-β-D-pyranoglucoside (A217)
[0636] The compound (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A217 (yield 55%). 1H NMR (500MHz, CDCl3) δ5.24(tdd,J=5.1,1.8,1.0Hz,1H),4.95(d,J=5.2Hz,1H),4.82(d,J=5.9Hz,1H),4.71(d,J=5.7Hz,1H),4.61(d,J=6.2Hz,1H),4 .20(t,J=4.5Hz,1H),3.98–3.88(m,2H),3.76–3.55(m,6H),3.29(ddd,J=1 0.8,7.4,4.7Hz,1H),3.00(d,J=10.8Hz,1H),2.23(tq,J=4.6,1.1Hz,1H), 1.95–1.81(m,2H),1.80–1.74(m,1H),1.77–1.72(m,1H),1.74–1.67(m,2H ),1.70–1.61(m,1H),1.63–1.55(m,1H),1.58–1.52(m,2H),1.55–1.49(m, 2H),1.50(dd,J=5.3,1.6Hz,2H),1.49–1.44(m,3H),1.47–1.40(m,1H),1. 44–1.26(m,4H),1.10(s,2H),0.99–0.88(m,17H).LRMS(ESI):605.4[M+H] +
[0637] Example 218 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-ursolic acid-17-(1'R)-(hydroxy)methyl-β-D-pyranoglucoside (A218)
[0638] The compound (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A218 (yield 56%). 1H NMR (500MHz, CDCl3) δ5.47 (tdd, J=4.9, 1.7, 1.0Hz, 1H), 4.95 (d, J=5.3Hz, 1H), 4.81 (dd, J=11.0, 5.7Hz, 2H) ,4.61(d,J=6.2Hz,1H),4.20(t,J=4.5Hz,1H),3.96(ddd,J=10.2,5.1,2.3Hz,1H),3.94–3.87(m,1H),3.76–3 .50(m,7H),3.29(ddd,J=10.8,7.4,4.7Hz,1H),3.00(d,J=10.8Hz,1H),2.06–1.24(m,25H),1.09(s,2H),0.9 7(d,J=1.5Hz,3H),0.95(d,J=1.5Hz,3H),0.93(d,J=1.5Hz,3H),0.93–0.89(m,10H).LRMS(ESI): 605.4[M+H] +
[0639] Example 219 (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-ursolic acid-28-β-D-pyranoglucoside (A219)
[0640] The compound (3S, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-28-O-benzyl-3-formyloleanolic acid was replaced with (3R, 5S, 8R, 9R, 10S, 14R, 17R, 18S)-17-formylursolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A219 (yield 56%). 1 H NMR (500MHz, CDCl3) δ5.53–5.46(m,2H),5.07(d,J=5.7Hz,1H),4.57(d,J=6.3Hz,1H),4.51(dd,J=8.8,2.6Hz, 1H),4.19(t,J=4.5Hz,1H),3.71–3.58(m,3H),3.58(dt,J=7.7,3.5Hz,1H),3.58–3.49(m,1H),3.36–3.25(m,2 H),3.00(d,J=10.8Hz,1H),2.28–2.22(m,1H),2.01–1.93(m,1H),1.89–1.24(m,21H),1.20(s,2H),0.99–0.93 (m,4H),0.96–0.90(m,8H),0.91(s,2H),0.91(d,J=5.7Hz,1H),0.90(d,J=1.5Hz,2H).LRMS(ESI): 603.4[M+H]+
[0641] Example 220 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-28-6"-O-methyl-β-D-pyranoglucuronide
[0642] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-tribenzyl-1-(pyridin-1-yl)sulfonyl-6-methoxy-β-D-pyranose glucosinolate. Compound (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A220 (yield 58%). 1 H NMR (500MHz, CDCl3) δ5.42 (d, J=5.8Hz, 1H), 5.33 (tdd, J=5.1, 1.8, 1.1Hz, 1H), 4.89 (d, J=6.4Hz,1H),4.77(d,J=6.3Hz,1H),4.50(dd,J=8.7,2.7Hz,1H),4.39(d,J=7.9Hz,1H) ,3.89–3.80(m,1H),3.73(s,2H),3.71–3.57(m,2H),2.48(ddd,J=12.4,6.5,4.0Hz,1H) ,2.40(ddd,J=12.5,6.6,4.0Hz,1H),2.17(tq,J=5.1,1.0Hz,1H),2.04(dddd,J=12.7,6. 4,5.1,1.0Hz,1H),1.95–1.87(m,1H),1.91–1.83(m,1H),1.83(dtt,J=7.1,2.7,1.5Hz, 2H),1.83–1.78(m,1H),1.72–1.65(m,2H),1.65(d,J=1.6Hz,1H),1.66–1.62(m,1H),1. 65–1.61(m,1H),1.64–1.52(m,3H),1.55–1.48(m,1H),1.51–1.29(m,5H),1.15(s,2H), 1.08(t,J=1.6Hz,5H),0.97(d,J=1.5Hz,3H),0.95–0.90(m,8H).LRMS(ESI): 629.4[M+H] + .
[0643] Example 221 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-28-6"-O-ethyl-β-D-pyranoglucopyranoside (A221)
[0644] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-tribenzyl-1-(pyridin-1-yl)sulfonyl-6-ethoxy-β-D-pyranose glucosinolate. Compound (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A221 (yield 53%). 1 H NMR (500MHz, CDCl3) δ5.42(d,J=5.8Hz,1H),5.33(tdd,J=5.1,1.8,1.1Hz,1H),4.95(d,J=6.4Hz,1H),4.77(d,J=6.3Hz,1H),4.51(dd,J=8.7,2.7Hz,1H ),4.45(d,J=8.2Hz,1H),4.21(qd,J=6.3,2.5Hz,2H),3.85(tdd,J=8.3,6.4 ,1.9Hz,1H),3.71–3.57(m,2H),2.48(ddd,J=12.5,6.5,4.0Hz,1H),2.40(dd d,J=12.5,6.6,4.0Hz,1H),2.17(tq,J=5.1,1.0Hz,1H),2.04(dddd,J=12.6 ,6.4,5.1,1.0Hz,1H),1.95–1.87(m,1H),1.91–1.83(m,1H),1.86–1.80(m, 2H),1.83–1.78(m,1H),1.72–1.29(m,14H),1.22–1.13(m,5H),1.08(t,J=1 .6Hz,5H),0.99–0.92(m,6H),0.93(d,J=6.6Hz,5H).LRMS(ESI):643.4[M+H] + .
[0645] Example 222 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-28-6"-O-2"'-fluoroethyl-β-D-pyranoglucopyranoside (A222)
[0646] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-tribenzyl-1-(pyridin-1-yl)sulfonyl-6-2-fluoroethyl-β-D-pyranose glucosinolate. Compound (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A222 (yield 53%). 1 H NMR (500MHz, CDCl3) δ6.11(s,1H),6.02(s,1H),5.42(d,J=5.8Hz,1H),5.33(tdd,J=5.1,1.8,1.1 Hz,1H),4.95(d,J=6.3Hz,1H),4.77(d,J=6.2Hz,1H),4.51(dd,J=8.7,2.7Hz,1H),3.93(d,J=8.2H z,1H),3.85(tdd,J=8.3,6.3,1.9Hz,1H),3.71–3.57(m,2H),2.48(ddd,J=12.5,6.5,4.0Hz,1H),2 .40(ddd,J=12.5,6.6,4.0Hz,1H),2.17(tq,J=5.1,1.0Hz,1H),2.04(dddd,J=12.6,6.4,5.1,1.0H z,1H),1.95–1.87(m,1H),1.91–1.84(m,1H),1.86–1.81(m,1H),1.84–1.78(m,2H),1.72–1.66(m, 1H),1.69–1.63(m,2H),1.66–1.62(m,1H),1.65–1.58(m,2H),1.62–1.51(m,2H),1.54–1.47(m,1H ),1.50–1.41(m,1H),1.44–1.36(m,2H),1.36(ddd,J=6.4,3.4,1.6Hz,1H),1.36–1.29(m,1H),1.1 5(s,2H),1.08(t,J=1.6Hz,5H),0.97(d,J=1.5Hz,3H),0.95–0.90(m,8H).LRMS(ESI): 647.4[M+H] + .
[0647] Example 223 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-17-(1'R)-(hydroxy)methyl-6"-O-methyl-β-D-pyranoglucopyranoside (A223)
[0648] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-tribenzyl-1-(pyridin-1-yl)sulfonyl-6-methoxy-β-D-pyranose glucosinolate. Compound (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A223 (yield 58%). 1 H NMR (500MHz, CDCl3) δ5.24 (tdd, J=5.1, 1.8, 1.0Hz, 1H), 4.99 (d, J=5.3Hz, 1H) ,4.87(d,J=6.4Hz,1H),4.75(d,J=5.7Hz,1H),4.62(d,J=6.1Hz,1H),4.09(d,J =7.5Hz,1H),3.93(ddd,J=7.3,5.7,2.5Hz,1H),3.84(dddd,J=8.3,7.5,6.4,1 .8Hz,1H),3.77–3.69(m,1H),3.73(s,3H),3.68–3.60(m,1H),3.56(tdd,J=8.3 ,6.1,2.6Hz,1H),2.48(ddd,J=12.4,6.5,4.0Hz,1H),2.40(ddd,J=12.5,6.6, 4.0Hz,1H),2.23(tq,J=4.6,1.1Hz,1H),1.99(dddd,J=12.6,6.4,5.2,1.0Hz,1 H),1.95–1.86(m,1H),1.89–1.78(m,3H),1.78–1.59(m,4H),1.59–1.26(m,11 H),1.11–1.05(m,8H),0.99–0.92(m,8H),0.90(s,2H).LRMS(ESI): 631.4[M+H] + .
[0649] Example 224 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyl ursolic acid-28-6"-O-methyl-β-D-pyranoglucopyranoside (A224)
[0650] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-tribenzyl-1-(pyridin-1-yl)sulfonyl-6-methoxy-β-D-pyranose glucosinolate. Compound (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl ursolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A224 (yield 62%). 1 H NMR (500MHz, CDCl3) δ5.50 (tdd, J=4.9, 1.8, 0.9Hz, 1H), 5.42 (d, J=5.8Hz, 1H), 4.89(d,J=6.4Hz,1H),4.77(d,J=6.3Hz,1H),4.55(dd,J=8.7,2.6Hz,1H),4.39( d,J=7.9Hz,1H),3.89–3.80(m,1H),3.73(s,2H),3.71–3.57(m,2H),2.48(ddd, J=12.5,6.5,4.0Hz,1H),2.40(ddd,J=12.5,6.6,4.0Hz,1H),2.28–2.22(m,1H), 2.06–1.91(m,2H),1.89–1.78(m,4H),1.77(ddd,J=12.5,7.7,5.2Hz,1H),1.73 –1.57(m,5H),1.60–1.55(m,1H),1.57–1.51(m,1H),1.47–1.39(m,2H),1.40(td ,J=2.1,1.1Hz,1H),1.41–1.31(m,2H),1.34–1.25(m,1H),1.20(s,2H),1.08(t, J=1.6Hz,5H),0.99–0.90(m,9H),0.91(d,J=2.0Hz,2H).LRMS(ESI): 629.4[M+H] + .
[0651] Example 225 (3S, 5S, 8R, 9R, 10S, 13R, 14R, 17S, 18R, 19R)-betulinic acid-28-6"-O-methyl-β-D-pyranoglucopyranoside (A225)
[0652] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-tribenzyl-1-(pyridin-1-yl)sulfonyl-6-methoxy-β-D-pyranose glucosinolate. Compound (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylbetulic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A225 (yield 50%). 1 H NMR (500MHz, CDCl3) δ5.42(d,J=5.9Hz,1H),4.89(d,J=6.4Hz,1H),4.83(h,J=1.4Hz,1H),4.77(d, J=6.3Hz,1H),4.67(h,J=1.6Hz,1H),4.51(dd,J=8.8,2.6Hz,1H),3.89–3.80(m,1H),3.73(s,2H), 3.71–3.57(m,2H),3.00(dddt,J=10.3,5.0,3.3,1.6Hz,1H),2.53–2.41(m,2H),1.86–1.34(m,26H ),1.13–1.05(m,7H),0.96(dd,J=12.7,1.5Hz,6H),0.85(t,J=1.4Hz,3H).LRMS(ESI): 629.4[M+H] + .
[0653] Example 226 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonylbetulinic acid-17-(1'R)-(hydroxy)methyl-6"-O-methyl-β-D-pyranoglucopyranoside (A226)
[0654] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranoglucoside was replaced by 2,3,4-O-tribenzyl-1-(pyridin-1-yl)sulfonyl-6-methoxy-β-D-pyranoglucoside. Compound (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formylbetulic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 2 to obtain A226 (yield 53%). 1H NMR (500MHz, CDCl3) δ4.99(d,J=5.3Hz,1H),4.87(d,J=6.4Hz,1H),4.81(h,J=1.4Hz,1H),4.69(d,J=5.3Hz,1H),4.67–4 .60(m,2H),4.09(d,J=7.5Hz,1H),3.91–3.80(m,2H),3.75–3.66(m,3H),3.66–3.52(m,2H),2.53–2.41(m,2H),2.13(ddd d,J=10.4,5.5,3.5,1.7Hz,1H),1.83(ddd,J=5.7,2.8,1.4Hz,1H),1.83–1.76(m,1H),1.73(q,J=1.4Hz,3H),1.63–1.28 (m,20H),1.13–1.05(m,7H),0.97(d,J=1.5Hz,3H),0.92(d,J=1.5Hz,3H),0.85(t,J=1.4Hz,3H).LRMS(ESI): 631.4[M+H] + .
[0655] Example 227 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonylbetulinic acid-17-(1'R)-(hydroxy)methyl-6"-O-methyl-β-D-pyranoglucopyranoside (A227)
[0656] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-tribenzyl-1-(pyridin-1-yl)sulfonyl-6-isopropoxy-β-D-pyranose glucosinolate. Compound (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A227 (yield 53%).1 H NMR (500MHz, CDCl3) δ5.42 (d, J=5.9Hz, 1H), 5.33 (tdd, J=5.1, 1.8, 1.1Hz, 1H), 5.0 3(hept,J=5.8Hz,1H),4.95(d,J=6.4Hz,1H),4.77(d,J=6.3Hz,1H),4.51(dd,J=8. 7,2.6Hz,1H),4.07(d,J=7.9Hz,1H),3.86(tdd,J=8.3,6.4,1.8Hz,1H),3.72–3.57 (m,2H),2.48(ddd,J=12.4,6.5,4.0Hz,1H),2.40(ddd,J=12.5,6.6,4.0Hz,1H),2.1 7(tq,J=5.1,1.0Hz,1H),2.04(dddd,J=12.7,6.4,5.1,1.0Hz,1H),1.95–1.87(m,1 H),1.91–1.83(m,1H),1.83(dddd,J=7.0,2.7,1.9,1.1Hz,2H),1.83–1.78(m,1H),1 .72–1.29(m,14H),1.25(d,J=5.7Hz,3H),1.20(d,J=5.9Hz,3H),1.15(s,2H),1.08 (t,J=1.6Hz,5H),0.97(d,J=1.5Hz,3H),0.95–0.90(m,8H).LRMS(ESI): 631.4[M+H] + .
[0657] Example 228 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-28-6"-O-cyclopropylmethyl-β-D-pyranoglucopyranoside (A228)
[0658] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-tribenzyl-1-(pyridin-1-yl)sulfonyl-6-cyclopropylmethoxy-β-D-pyranose glucosinolate. Compound (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A228 (yield 54%). 1H NMR (500MHz, CDCl3) δ5.42 (d, J=5.8Hz, 1H), 5.33 (tdd, J=5.1, 1.8, 1.1Hz, 1H), 4.95 (d ,J=6.4Hz,1H),4.77(d,J=6.3Hz,1H),4.51(dd,J=8.7,2.7Hz,1H),4.12–4.05(m,3H),3 .85(tdd,J=8.2,6.3,1.8Hz,1H),3.71–3.57(m,2H),2.48(ddd,J=12.5,6.5,4.0Hz,1H) ,2.40(ddd,J=12.5,6.6,4.0Hz,1H),2.17(tq,J=5.1,1.0Hz,1H),2.04(dddd,J=12.6,6 .4,5.1,1.0Hz,1H),1.95–1.83(m,2H),1.86–1.78(m,3H),1.72–1.66(m,1H),1.69–1. 63(m,2H),1.66–1.62(m,1H),1.65–1.47(m,6H),1.50–1.41(m,1H),1.44–1.36(m,2H), 1.36(ddd,J=6.4,3.4,1.6Hz,1H),1.36–1.29(m,1H),1.15(s,2H),1.08(t,J=1.6Hz,5H ),0.97(d,J=1.5Hz,3H),0.95–0.90(m,8H),0.58–0.44(m,4H).LRMS(ESI): 669.4[M+H] + .
[0659] Example 229 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-28-6"-N-ethyl-β-D-pyranoglucopyranoside (A229)
[0660] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-tribenzyl-1-(pyridin-1-yl)sulfonyl-6-ethylamino-β-D-pyranose glucosinolate. Compound (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyloleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyloleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A229 (yield 58%). 1H NMR(500MHz,CDCl3)δ7.28(t,J=3.9Hz,1H),5.46–5.39(m,1H),5.33(tdd,J=5.1,1.8,1.1Hz,1H),4.89(d,J=6.1Hz,1H),4.78–4.71(m,1H),4.5 0–4.43(m,1H),4.09(d,J=7.5Hz,1H),3.81–3.72(m,1H),3.68–3.57(m, 2H),3.23(qd,J=6.2,3.9Hz,2H),2.48(ddd,J=12.5,6.5,4.0Hz,1H),2.4 0(ddd,J=12.5,6.6,4.0Hz,1H),2.17(tq,J=5.1,1.0Hz,1H),2.04(dddd,J=12.6,6.4,5.1,1.0Hz,1H),1.95–1.84(m,2H),1.86–1.81(m,1H),1. 84–1.78(m,2H),1.72–1.29(m,14H),1.21–1.13(m,5H),1.08(t,J=1.6H z,6H),0.99–0.92(m,6H),0.93(d,J=6.6Hz,5H).LRMS(ESI):642.4[M+H] + .
[0661] Example 230 (5S, 8R, 9R, 10S, 14R, 17R, 18S)-3-Carbonyloleanolic acid-28-6"-N-2"'-fluoroethyl-β-D-pyranoglucuronide (A230)
[0662] 2,3,4,6-O-tetrabenzyl-1-(pyridin-1-yl)sulfonyl-β-D-pyranose glucosinolate was replaced by 2,3,4-O-tribenzyl-1-(pyridin-1-yl)sulfonyl-6-2-fluoroethylamino-β-D-pyranose glucosinolate. Compound (3S,5S,8R,9R,10S,14R,17R,18S)-28-O-benzyl-3-formyl oleanolic acid was replaced by (5S,8R,9R,10S,14R,17R,18S)-3-carbonyl-17-formyl oleanolic acid. The remaining raw materials, reagents and preparation methods were the same as those in Example 10 to obtain A230 (yield 51%). 1H NMR(500MHz, CDCl3)δ7.80(t,J=4.9Hz,1H),5.46–5.39(m,1H),5.33(tdd,J=5.1, 1.8,1.1Hz,1H),4.89(d,J=6.1Hz,1H),4.78–4.71(m,1H),4.58(td,J=3.4,2.3Hz, 1H),4.53–4.43(m,2H),4.05(d,J=7.4Hz,1H),3.81–3.72(m,1H),3.68–3.57(m,2H ),3.44(dtd,J=4.6,3.4,1.2Hz,1H),3.39(dtd,J=4.8,3.4,1.1Hz,1H),2.48(ddd, J=12.5,6.5,4.0Hz,1H),2.40(ddd,J=12.5,6.6,4.0Hz,1H),2.17(tq,J=5.1,1.0H z,1H),2.04(dddd,J=12.6,6.4,5.1,1.0Hz,1H),1.95–1.87(m,1H),1.91–1.84(m, 1H),1.86–1.81(m,1H),1.84–1.78(m,2H),1.72–1.29(m,14H),1.15(s,2H),1.08( t,J=1.6Hz,6H),0.99–0.92(m,6H),0.93(d,J=6.6Hz,5H).LRMS(ESI): 650.4[M+H] + .
[0663] Pharmacological Activity Test Example
[0664] Example 1. Determination of the hypoglycemic pharmacodynamic activity of the compounds of the present invention in vivo
[0665] 1. Pharmacodynamics of the compound in ICR mice for oral glucose tolerance
[0666] 1. Experimental Materials:
[0667] Table 1: Animal usage table
[0668]
[0669]
[0670] After the animals arrived at the WuXi AppTec facility, they were kept in an animal breeding room with strictly controlled environmental conditions. The temperature in the breeding room was maintained at 20-24°C and the humidity was maintained at 30-70%. The temperature and humidity in the breeding room were monitored in real time by a thermometer and hygrometer, and the temperature and humidity were recorded twice a day (once in the morning and once in the afternoon). The lighting in the animal breeding room was controlled by an electronic timed lighting system, with the lights on for 12 hours and off for 12 hours a day (on at 7:00 am and off at 19:00 pm). During the experiment, the animals were kept in single cages and toys were provided to the mice in each cage. During the experiment, the animals had free access to food (growth / breeding feed for rats and mice) and drinking water.
[0671] After the animals arrive, they need to adapt to the environment for 1 to 2 weeks before experiments can be carried out.
[0672] 2. Drug preparation and administration:
[0673] Table 2: Comparative solvent information
[0674]
[0675] 1) Preparation of drug solutions: Each compound was prepared on the first day of the experiment and then stored in a refrigerator at 4°C for use on the next day.
[0676] 2) Drug administration: After grouping, each group of animals was administered 0.5 hours before sugar administration.
[0677] 3) Oral glucose tolerance test: 0.5 hours after the animals were given the drug, the animals were gavaged with glucose, and the time of glucose administration was recorded as 0 minutes. The oral glucose dose was 5g / kg, 10ml / kg, and the blood glucose of the animals was tested before administration, before glucose administration, and 15, 30, 60, 90, and 120 minutes after glucose administration. Blood glucose was tested using a blood glucose meter and matching blood glucose test strips.
[0678] 3. Experimental results:
[0679] The results showed that oral administration of pentacyclic triterpenoid glycosides could effectively reduce the postprandial blood glucose level in ICR mice. Figure 1 ), among which A25 and A43 had the best hypoglycemic activity, with a more obvious hypoglycemic effect at a dose of 25 mg / kg, and the hypoglycemic effect was further enhanced at a dose of 50 mg / kg ( Figure 2 ).
[0680] Example 2: Determination of the GLP-1 secretion promoting activity of the compounds of the present invention in vitro
[0681] 1. Experimental materials:
[0682] Cell line: Intestinal endocrine cell line STC-1 cells
[0683] Negative control: DMSO
[0684] Positive control: INT777 (TGR5 receptor agonist)
[0685] Detection tool: HTRF kit
[0686] Others: KRBH buffer, BSA, DPP4 inhibitor
[0687] 2. Experimental methods:
[0688] STC-1 cells were plated at a certain density, and after the cells adhered overnight, they were starved with KRBH buffer.
[0689] BSA maintained nutrition, DPP4 inhibitors reduced GLP-1 degradation, and after 1 hour, KRBH buffer without or with glucose was used to stimulate GLP-1 secretion. A certain concentration of compound was added at the same time. After 1 hour of treatment, the supernatant was collected and the GLP-1 concentration was detected using the HTRF kit. At the same time, LDH secretion was detected to indicate the toxicity of the compound.
[0690] 3. Experimental results:
[0691] The experimental results showed that A64 has a good effect of promoting GLP-1 secretion in vitro, and its in vitro EC50 is 7.231μM.
[0692] Significantly better than the positive compound INT777 (EC50 = 22.82 μM) ( Figure 3 ).
[0693] Example 3: Determination of in vitro anti-influenza virus pharmacodynamic activity of the compounds of the present invention
[0694] 1. Experimental Materials:
[0695] Cell lines:MDCK cells
[0696] Negative control:DMSO
[0697] Positive control:Zanamivir / Oseltamivir(50μM)
[0698] Luminescent Cell Viability Assay
[0699] Compound stock solution preparation: Compounds 1-7 diluted to 10mM / L; screening concentration: 50μM
[0700] 2. Experimental methods:
[0701] MDCK cells were plated in 96-well plates (1×104 / well), and cultured in an incubator at 37°C and 5% CO2 for 24 h before adding drugs.
[0702] After adding the drug, the 96-well plate was placed in an incubator at 37°C and 5% CO2 for 36 h and detected by an enzyme-labeled instrument.
[0703] 3. Experimental results:
[0704] Inhibition rate calculation formula: I (inhibition rate) = [1-(Xi-Xj) / (Yi-Yj)] × 100%
[0705] Xi: number of surviving cells in the test group without virus added; Xj: number of surviving cells in the test group with virus added
[0706] Yi: Number of surviving cells in the DMSO group without virus addition; Yj: Number of surviving cells in the DMSO group with virus addition
[0707] The results showed that pentacyclic triterpenoid carbon glycosides can produce effective anti-influenza virus pharmacological activity, among which A2 showed the same virus inhibition rate and low cytotoxicity as the positive drug zanamivir, and similar virus inhibition rate as the positive drug ribavirin, but the cytotoxicity was lower than ribavirin ( Figure 4 ).
[0708] Example 4: In vitro affinity determination of the compounds of the present invention for coronavirus N protein
[0709] 1. Experimental materials:
[0710] N protein diluent: 20 μg / mL
[0711] Buffer: 10 mM HEPES, pH 7.4, 150 mM NaCl, 3.0 mM EDTA, and 0.005% (v / v) surfactant P20, 5% DMSO.
[0712] Instrument: Biacore 8K (GE Healthcare)
[0713] 2. Test methods:
[0714] The affinity of the compound to the N protein was tested by surface plasmon resonance (SPR) using Biacore 8K (GE Healthcare). At 25°C, the N protein was first diluted to 20 μg / mL, and the full-length N protein was coupled to the CM5 chip using the standard amino coupling method, with a signal value of 10,000 signal units (RU). The running buffer used was 10 mM HEPES, pH 7.4, 150 mM NaCl, 3.0 mM EDTA, and 0.005% (v / v) surfactant P20, 5% DMSO. The 10 mM DMSO stock solution of the test compound was diluted to 7 gradient concentrations (1.56 μM-100 μM) using the running buffer. During the test, the instrument was initialized and run 3 times with the running buffer, and the test compound was injected and flowed through the chip in sequence, and the binding and dissociation times were set to 100 seconds. After one cycle, 50% DMSO was used to wash away the compounds remaining on the chip, and the next cycle was continued. Finally, solvent correction was performed using a running buffer containing 4.5%-5.8%. Based on the generated spectrum, the control group values were deducted and solvent correction was performed, and the generated data were used to calculate the KD value using the static affinity model according to the fixed Rmax value method using Biacore 8K data processing software.
[0715] 3. Experimental conclusion:
[0716] The results showed that pentacyclic triterpene glycosides had enhanced affinity with N protein, and the Ki of some compounds was <10μM. Figure 5 , Figure 6 )
[0717] Example 5: Determination of the in vitro anti-SARS-Cov-2 virus pharmacodynamic activity of the compounds of the present invention
[0718] 1. Experimental materials:
[0719] Vero E6 cells (ATCC-1586)
[0720] 48-well plate (50,000 cells / well); 96-well plate (20,000 cells / well)
[0721] 2019-nCoV(nCoV-2019BetaCoV / WIV04 / 2019)
[0722] 2. Experimental methods:
[0723] Vero E6 cells (ATCC-1586) were plated in 48-well plates (50,000 cells / well), and 100 μL / well of medium containing gradient concentrations of compounds was added, followed by the addition of 2019-nCoV (nCoV-2019BetaCoV / WIV04 / 2019), with a multiplicity of infection (MOI) of 0.05. After 1 hour of co-incubation, the supernatant was aspirated, washed, and 200 μL / well of medium containing gradient concentrations of compounds was added again, and cultured at 37°C for 24 hours. After 24 hours, the cell supernatant was collected, the supernatant viral RNA was extracted, and the supernatant viral copy number was detected by real-time fluorescence quantitative PCR. The compound inhibition rate was calculated based on the viral copy number, and the EC of the compound was calculated using Prism 6.0. 50 .
[0724] Vero E6 cells (ATCC-1586) were plated in 96-well plates (20,000 cells / well), and 100 μL / well of medium containing gradient concentrations of compounds was added. After 24 hours, the effect of the compounds on cell activity was detected using the CCK8 detection kit, and the CC of the compounds was calculated using Prism 6.0. 50 .
[0725] 3. Experimental conclusion:
[0726] The results showed that pentacyclic triterpenoid glycosides can effectively inhibit the replication of SARS-Cov-2 virus, among which A104 and A114 have EC50 of 3.6μM and 4.6μM, and some compounds have an inhibition rate of 100% at the level of 10μM ( Figure 7 , Figure 8 ).
[0727] Example 6: Determination of PK properties of the compounds of the present invention in mice
[0728] 1. Experimental materials:
[0729] Animal Condition:
[0730] Species / strain: ICR (CD-1) mice
[0731] Sex / number of mice: male (n=6)
[0732] Weight(g):Male(20-24g)
[0733] Diet Type: Standard rodent diet
[0734] Water Any
[0735] Fast for 12 hours before administration and maintain fasting for 2 hours.
[0736] Animal housing: The animal room was environmentally controlled (target conditions: temperature 18 to 29°C, relative humidity 30 to 70%. Temperature and relative humidity were monitored daily. An electronic time-controlled lighting system was used to provide a 12-hour light / 12-hour dark cycle.
[0737] 2. Test methods:
[0738] The dosage is as follows:
[0739]
[0740] 3. Experimental conclusion:
[0741] The results show that the pentacyclic triterpene carbon glycoside compounds of the present invention have good pharmacokinetic properties. The specific conclusions are shown in Fig. 9 , Fig.10 . Fig. 9 The results show that the compounds of the present invention can achieve the desired drug exposure within the experimental time after oral and enteral administration. Fig.10 It was shown that the compound of the present invention was rapidly released within 8 hours after administration and completely released within 24 hours.
[0742] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A pentacyclic triterpene carbonyl glycoside derivative compound selected from the group consisting of:
2. A pharmaceutical composition, It is characterized in that The pharmaceutical composition contains a therapeutically effective amount of the compound according to claim 1 and / or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, excipients, adjuvants, auxiliary materials and / or diluents.
3. Use of a compound or a pharmaceutically acceptable salt selected from the following group in the preparation of a medicament for treating or preventing metabolic diseases associated with diabetes:
4. The use according to claim 3, It is characterized in that The disease is selected from the group consisting of diabetes and obesity.
5. Use of a compound or a pharmaceutically acceptable salt selected from the following group in the preparation of a method for treating or preventing viral diseases; in, The viral disease is a disease caused by influenza virus:
6. Use of a compound or a pharmaceutically acceptable salt selected from the following group in the preparation of a method for treating or preventing viral diseases; in, The viral disease is a disease caused by coronavirus:
Citation Information
Patent Citations
Ursolic acid chemical modified compound amine having antitumor activity
CN101161670A
2-hydroxyl-3-deoxidized pentacyclic triterpenoid and derivant, preparation method and uses thereof
CN101367861A
Taxane derivative, and preparation and use thereof
CN101463029A
Pentacylic triterpanes-vitamin C conjugates as well as preparation method and medical application thereof
CN101607979A
Oleanolic acid derivatives and application thereof serving as alpha-glucosidase inhibitor
CN101724007A
